Patent Application
20230159989
This application includes and incorporates by reference in its entirety a Sequence Listing XML in the required .xml format. The Sequence Listing XML file that has been electronically filed contains the information of the nucleotide and/or amino acid sequences disclosed in the patent application using the symbols and format in accordance with the requirements of 37 C.F.R. §§ 1.832 through 1.834.
The Sequence Listing XML filed herewith serves as the electronic copy required by § 1.834(b)(1).
The Sequence Listing XML is identified as follows: “KANVAS_003_SEQ_LIST.xml” (1649 kilo bytes in size), which was created on Nov. 22, 2022.
This disclosure relates to methods for highly-multiplexed, rapid detection of nucleotides in samples, and constructs to be used in said methods.
Microbes, both individually and in communities (i.e. microbiomes), play a large role in human health and disease. Conventional methods to study biologically and clinically relevant aspects of these microbes, including antimicrobial resistance, suffer from long turnaround times and are limited in the number of taxa and genetic elements they can profile. As a result, researchers are left with an incomplete understanding of microbiota in their native biological contexts. In addition, clinicians are faced with diagnostic delays that are detrimental to patient care, which increases the risk of patient morbidity and mortality.
Antimicrobial resistance is an emerging threat to global public health. Current tests available in clinical laboratories are time-consuming and limited in scope for antimicrobial resistance profile measurement. Timely and accurate information on pathogen identity and their associated antimicrobial susceptibility profile is critical in helping clinicians treat patients with shorter response time and higher precision. In addition, many other microbial phenotypes, such as persistence, tolerance, motility, hyphae formation, spore formation, and quorum sensing, can provide useful biological and clinical information, but are difficult to measure using standard sequencing techniques. The present disclosure provides methods for microbial identification and rapid antimicrobial susceptibility profile measurement or other microbial phenotype measurements. These methods combine a short period of culturing with known concentrations of antimicrobial drugs, or other alterations to the environment, with a highly multiplexed fluorescence readout to distinguish cellular taxonomic identity and susceptibility to different classes of antimicrobials or other relevant microbial phenotypes. This approach will enable a rapid and cost-effective test that can be deployed in clinical settings for fast diagnosis of infectious agents and proper selection of antimicrobial drugs for treatment.
The present disclosure provides methods that combine single-cell imaging, single-molecule imaging, microfluidic technologies, and phenotypic antimicrobial susceptibility testing to enable rapid identification of microbial species, current antimicrobial susceptibility profile, and future antimicrobial susceptibility profile, directly from patient samples. The present disclosure also provides methods that enable the detection of millions or billions of potential nucleic acid based targets in a single assay.
The present disclosure provides methods that can rapidly identify microbial species, genera, families, orders, classes, and phyla associated with a particular tissue or specimen. In further embodiments, the present disclosure provides methods to rapidly determine any antimicrobial drugs or compounds the identified microbial species is susceptible to or to which the microbial species may become susceptible in the future.
In some aspects, the present disclosure provides methods of characterizing a microbial cell from a biological sample, the method comprising a) directly inoculating the microbe onto a device; b) identifying the microbe; and c) detecting susceptibility to one or more antimicrobial agents.
In some aspects, the present disclosure provides methods of characterizing a microbial cell from a biological sample, the method comprising a) directly inoculating the microbe onto a device; b) identifying the microbe; and c) detecting future susceptibility to one or more antimicrobial agents.
In some embodiments, the sample is not subjected to culturing before the microbe is inoculated onto the device. In some embodiments, the microbe in the sample is cultured for one to 12 cell divisions before it is inoculated onto the device. In some embodiments, the microbe in the sample is cultured for one to numerous cell divisions before it is inoculated onto the device. The number of cell divisions depends on the species doubling time, which can be variable.
In some embodiments, the microbe is identified by in situ hybridization. In some embodiments, the microbe is identified by fluorescence in situ hybridization (FISH). In some embodiments, the fluorescence in situ hybridization is high-phylogenetic-resolution fluorescence in situ hybridization (HiPR-FISH).
In some embodiments, the microbe is further characterized via live-cell imaging or growth dynamics calculation while in situ hybridization is performed.
In some embodiments, the microbe is identified by hybridization of a bar-coded probe a 16S ribosomal RNA sequence in the microbe, 5S ribosomal RNA sequence in the microbe, and/or 23S ribosomal RNA sequence in the microbe. In some embodiments, the in situ hybridization is multiplexed. In some embodiments, the susceptibility to one or more microbial agents is determined by measuring the minimum inhibitory concentration of the microbe when exposed to an antimicrobial agent. In some embodiments, the susceptibility to one or more microbial agents is determined by measuring microbial cell metabolism when the microbe is exposed to an antimicrobial agent. In some embodiments, microbial cell metabolism is measured by determining the concentration of dissolved carbon dioxide, oxygen consumption of microbes in the sample, expression of genes involved in cell division and/or growth, or expression of stress response genes. In some embodiments, microbial cell susceptibility is determined by a live/dead stain. In some embodiments, wherein microbial cell susceptibility is determined by cell number. In some embodiments, microbial cell susceptibility is determined by detecting the presence or absence of one or more antimicrobial genes in the microbial cell. In some embodiments, microbial cell susceptibility is determined by detecting the presence or absence of one or more gene mutations associated with the development of antimicrobial resistance or susceptibility in the microbial cell. In some embodiments, future microbial cell susceptibility is determined by detecting the presence or absence of one or more antimicrobial genes in the microbial cell. In some embodiments, future microbial cell susceptibility is determined by detecting the presence or absence of one or more gene mutations associated with the development of antimicrobial resistance or susceptibility in the microbial cell.
In some embodiments, wherein the one or more gene mutations associated with the development of antimicrobial resistance or susceptibility is selected from deletions, duplications, single nucleotide polymorphisms (SNPs), frame-shift mutations, inversions, insertions, and/or nucleotide substitutions. In some embodiments, the one or more antimicrobial genes is selected from: genes encoding multidrug resistance proteins (e.g. PDR1, PDR3, PDR7, PDR9), ABC transporters (e.g. SNQ2, STE6, PDR5, PDR10, PDR11, YOR1), membrane associated transporters (GAS1, D4405), soluble proteins (e.g. G3PD), RNA polymerase, rpoB, gyrA, gyrB, 16S RNA, 23S rRNA, NADPH nitroreductase, sul2, strAB, tetAR, aac3-iid, aph, sph, cmy-2, floR, tetB; aadA, aac3-VIa, and sul1. In some embodiments, the presence or absence of one or more antimicrobial genes, or the gene mutation associated with the development of antimicrobial resistance or susceptibility in the microbial cell is detected using in situ hybridization. In some embodiments, the presence or absence of one or more antimicrobial genes, or the gene mutation associated with the development of antimicrobial resistance or susceptibility in the microbial cell is detected using fluorescence in situ hybridization (FISH). In some embodiments, the fluorescence in situ hybridization is high-phylogenetic-resolution fluorescence in situ hybridization (HiPR-FISH).
In some embodiments, the identification of the microbial cell and the detection of susceptibility or future susceptibility to one or more antimicrobial agents occurs sequentially.
In some embodiments, the identification of the microbial cell and the detection of susceptibility or future susceptibility to one or more antimicrobial agents occurs simultaneously.
In some embodiments, the identification of the microbial cell and the detection of susceptibility or future susceptibility to one or more antimicrobial agents occurs in parallel.
In some embodiments, the biological sample is obtained from a patient. In some embodiments, the biological sample is obtained from a patient diagnosed with or believed to be suffering from an infection or disorder. In some embodiments, the disease or disorder is an infection. In some embodiments, the infection is a bacterial, viral, fungal, or parasitic infections. In some embodiments, the bacterial infection is selected from Mycobacterium, Streptococcus, Staphylococcus, Shigella, Campylobacter, Salmonella, Clostridium, Corynebacterium, Pseudomonas, Neisseria, Listeria, Vibrio, Bordetella, E. coli (including pathogenic E. coli), Pseudomonas aeruginosa, Enterobacter cloacae, Mycobacterium tuberculosis, Staphylococcus aureus, Helicobacter pylori, Legionella, Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus saprophyticus, and Streptococcus agalactiae, or a combination thereof. In some embodiments, the viral infection is selected from Helicobacter pylori, infectious haematopoietic necrosis virus (IHNV), Parvovirus B19, Herpes Simplex Virus, Varicella-zoster virus, Cytomegalovirus, Epstein-Barr virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Measles virus, Mumps virus, Rubella virus, Human Immunodeficiency Virus (HIV), Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, Norovirus, Zika Virus, Dengue Virus, Rabies Virus, Newcastle Disease Virus, and White Spot Syndrome Virus, or a combination thereof. In some embodiments, the fungal infection is selected from Aspergillus, Candida, Pneumocystis, Blastomyces, Coccidioides, Cryptococcus, and Histoplasma, or a combination thereof. In some embodiments, the parasitic infection is selected from Plasmodium (i.e. P. falciparum, P. malariae, P. ovale, P. knowlesi, and P. vivax), Trypanosoma, Toxoplasma, Giardia, and Leishmania, Cryptosporidium, helminthic parasites: Trichuris spp. (whipworms), Enterobius spp. (pinworms), Ascaris spp. (roundworms), Ancylostoma spp. and Necator spp. (hookworms), Strongyloides spp. (threadworms), Dracunculus spp. (Guinea worms), Onchocerca spp. and Wuchereria spp. (filarial worms), Taenia spp., Echinococcus spp., and Diphyllobothrium spp. (human and animal cestodes), Fasciola spp. (liver flukes) and Schistosoma spp. (blood flukes), or a combination thereof.
In some embodiments, the biological sample is selected from bronchoalveolar lavage fluid (BAL), blood, serum, plasma, urine, cerebrospinal fluid, pleural fluid, synovial fluid, ocular fluid, peritoneal fluid, amniotic fluid, gastric fluid, lymph fluid, interstitial fluid, tissue homogenate, cell extracts, saliva, sputum, stool, physiological secretions, tears, mucus, sweat, milk, semen, seminal fluid, vaginal secretions, fluid from ulcers and other surface eruptions, blisters, and abscesses, and extracts of tissues including biopsies of normal, malignant, and suspect tissues or any other constituents of the body which may contain the microorganism of interest. In some embodiments, the biological sample is a human oral microbiome sample. In some embodiments, the biological sample is a whole organism.
In another aspect, a method for analyzing a sample can include:
In certain embodiments, the first emissive readout probe sequence can be the same length as the first landing pad sequence.
In certain embodiments, the first emissive readout probe sequence can be at least 2 nucleotides longer than the first landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be the same length as the second landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be at least 2 nucleotides longer than the second landing pad sequence.
In another aspect, a method for analyzing a sample can include:
In certain embodiments, the emissive readout probe sequence can be the same length as the first or second landing pad sequence.
In certain embodiments, the emissive readout probe sequence can be at least 2 nucleotides longer than the first or second landing pad sequence.
In another aspect, a construct can include:
In certain embodiments, the first emissive readout probe sequence can be the same length as the first landing pad sequence.
In certain embodiments, the first emissive readout probe sequence can be at least 2 nucleotides longer than the first landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be the same length as the second landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be at least 2 nucleotides longer than the second landing pad sequence.
In another aspect, a library of constructs comprising a plurality of barcoded probes, wherein each barcoded probe comprises:
In certain embodiments, the first emissive readout probe sequence can be the same length as the first landing pad sequence.
In certain embodiments, the first emissive readout probe sequence can be at least 2 nucleotides longer than the first landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be the same length as the second landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be at least 2 nucleotides longer than the second landing pad sequence.
In another aspect, a method for analyzing a bacterial sample can include:
In certain embodiments, the first emissive readout probe sequence can be the same length as the first landing pad sequence.
In certain embodiments, the first emissive readout probe sequence can be at least 2 nucleotides longer than the first landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be the same length as the second landing pad sequence.
In certain embodiments, the second emissive readout probe sequence can be at least 2 nucleotides longer than the second landing pad sequence.
In another aspect, a method for analyzing a bacterial sample can include:
In certain embodiments, the emissive readout probe sequence can be the same length as the first or second landing pad sequence.
In certain embodiments, the emissive readout probe sequence can be at least 2 nucleotides longer than the first or second landing pad sequence.
Other aspects, embodiments, and features will be apparent from the following description, the drawings, and the claims.
It is to be appreciated that certain aspects, modes, embodiments, variations, and features of the present methods and compositions are described below in various levels of detail in order to provide a substantial understanding of the present disclosure.
Where values are described as ranges, endpoints are included. Furthermore, it will be understood that such disclosure includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated.
“5′-end” and “3′-end” refers to the directionality, e.g., the end-to-end orientation of a nucleotide polymer (e.g., DNA). The 5′-end of a polynucleotide is the end of the polynucleotide that has the fifth carbon.
The term “about,” as used herein, refers to +/−10% of a recited value.
“Complementary” refers to the topological compatibility or matching together of interacting surfaces of two nucleotides as understood by those of skill in the art. Thus, two sequences are “complementary” to one another if they are capable of hybridizing to one another to form a stable anti-parallel, double-stranded nucleic acid structure. A first nucleotide is complementary to a second nucleotide if the nucleotide sequence of the first nucleotide is substantially identical to the nucleotide sequence of the nucleotide binding partner of the second nucleotide, or if the first nucleotide can hybridize to the second nucleotide under stringent hybridization conditions. Thus, the nucleotide whose sequence is 5′-TATAC-3′ is complementary to a nucleotide whose sequence is 5′-GTATA-3′.
“Nucleotides,” “Nucleic acids,” “polynucleotide” or “oligonucleotide” refer to a polymeric-form of DNA and/or RNA (e.g., ribonucleotides, deoxyribonucleotides, or analogs thereof) of any length; e.g., a sequence of two or more ribonucleotides or deoxyribonucleotides. As used herein, the term “nucleotides” includes double- and single-stranded DNA, as well as double- and single-stranded RNA; it also includes modified and unmodified forms of a nucleotide (modifications to and of a nucleotide, for example, can include methylation, phosphorylation, and/or capping). In some embodiments, a nucleotide can be one of the following: a gene or gene fragment; genomic DNA; genomic DNA fragment; exon; intron; messenger RNA (mRNA); transfer RNA (tRNA); ribosomal RNA (rRNA); ribozyme; cDNA; recombinant nucleotide; branched nucleotide; plasmid; vector; isolated DNA of any sequence; isolated RNA of any sequence; any DNA described herein, any RNA described herein, primer or amplified copy of any of the foregoing.
In some embodiments, nucleotides can have any three-dimensional structure and may perform any function, known or unknown. The structure of nucleotides can also be referenced to by their 5′- or 3′-end or terminus, which indicates the directionality of the nucleotide sequence. Adjacent nucleotides in a single-strand of nucleotides are typically joined by a phosphodiester bond between their 3′ and 5′ carbons. However, different internucleotide linkages could also be used, such as linkages that include a methylene, phosphoramidate linkages, etc. This means that the respective 5′ and 3′ carbons can be exposed at either end of the nucleotide sequence, which may be called the 5′ and 3′ ends or termini. The 5′ and 3′ ends can also be called the phosphoryl (PO4) and hydroxyl (OH) ends, respectively, because of the chemical groups attached to those ends. The term “nucleotides” also refers to both double- and single-stranded molecules.
In some embodiments, nucleotides can include modified nucleotides, such as methylated nucleotides and nucleotide analogs (including nucleotides with non-natural bases, nucleotides with modified natural bases such as aza- or deaza-purines, etc.). If present, modifications to the nucleotide structure can be imparted before or after assembly of the nucleotide sequence.
In some embodiments, the sequence of nucleotides can be interrupted by non-nucleotide components. One or more ends of the nucleotides can be protected or otherwise modified to prevent that end from interacting in a particular way (e.g. forming a covalent bond) with other nucleotides.
In some embodiments, nucleotides can be composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T). Uracil (U) can also be present, for example, as a natural replacement for thymine when the nucleotide is RNA. Uracil can also be used in DNA. Thus, the term “sequence” refers to the alphabetical representation of nucleotides or any nucleic acid molecule, including natural and non-natural bases.
When used in terms of length, for example 20 nt, “nt” refers to nucleotides.
As used herein a “taxon” refers to a group of one or more populations of an organism or organisms. In some embodiments, a “taxon” refers to a phylum, a class, an order, a family, a genus, a species, or a train. In some embodiments, the disclosure includes providing a list of taxa of microorganisms. In some embodiments, the list of taxa of microorganisms is selected from a list of phyla, a list of classes, a list of orders, a list of families, a list of genera, or a list of species, of microorganisms.
In analysis of a sample, a species can be a target of interest. For example, a species can include a taxonomic species.
In the event of any term having an inconsistent definition between this application and a referenced document, the term is to be interpreted as defined herein.
The development of antimicrobial resistance among infectious organisms is an emerging problem in patient treatment. Some microbial organisms have even become resistant to multiple classes of antimicrobials, leading to increasing incidences of potentially fatal infections that cannot be treated with available antimicrobials. In some cases, microbes possessing more than one antimicrobial gene may only begin expressing one or more of these genes after exposure to antimicrobials. Currently, microbiology laboratories in hospitals and clinics rely on culturing bacteria from patient samples before species identification or antimicrobial susceptibility testing, however culturing bacteria is time-consuming and labor-intensive. Furthermore, many microorganisms are not readily culturable.
In a typical clinical lab workflow, the culturing step involves plating patient samples on an agar substrate and waiting for individual bacterium to grow into macroscopic colonies, each containing 10 to 100 million cells. Depending on the species of bacteria, this process can take between 24 hours to several days, which leads to a significant time delay from sampling to diagnosis. In addition, culturing bacteria requires a technician to prepare the culture plates by hand and evaluate bacterial growth by eye. Both of these factors add unnecessary hands-on time for the technician, and further increase the amount of time required for diagnosis. In certain classes of diseases such as sepsis, a delayed diagnosis can mean life or death for the patient.
The key innovative step of this method is to implement parallel single-cell imaging for microbial identification and characterization, which identification of microbial genera and species, and assessment of growth under different antimicrobial conditions directly on individual microbial cells or small colonies of cells, without the need to wait for cells to grow and divide into colonies containing millions to billions of cells.
Cell division events or microbial morphology changes can be monitored via iterative imaging of the sample during culture, or at the conclusion of culturing and following fixation, to measure microbial growth and stress in a solution with a given concentration of antimicrobials. Because the observation of only a few cell division events is sufficient to assess susceptibility or resistance of the microbial species to an antimicrobial agent, this technique can provide definitive results in less time than a complete cell cycle. This process is orders of magnitude faster than current techniques. For example, in a population of 1000 asynchronously dividing cells, the mean waiting time for the next division event to occur is 1/1000 of the duration of the typical cell cycle. For example, if the bacteria is E. coli, with an average cell division time of 20 minutes, the next event occurs after roughly one second. The parallel observation of many (thousands and more) cells also enables the construction of division time distribution for accurate determination of growth rate over a time duration of one or few cell cycles. In some embodiments, the cells may be allowed to grow for a defined period of time. After the growth period, the samples can be fixed and observed on a microscope. In some cases, growth is measured by counting the number of micro colonies present in the sample. In other embodiments, the cells may be observed on a microscope while they are growing. In some embodiments, after acquiring the necessary growth and stress data, the sample can be fixed directly and parallel single-cell imaging performed to read out the species identity of the microorganism of interest. This may be followed up with single molecule imaging to measure the presence of genes that may indicate current or future susceptibility to antimicrobials. The micro-colony level or single-cell level observation will drastically cut down the time required to go from sample to diagnosis, requiring on average a few (e.g. one, two, or three) cell divisions to occur before the readout step, and will provide clinicians with actionable information earlier than any existing technology. Furthermore, the present methods provide clinicians with the antimicrobial susceptibility information needed to deploy targeted antimicrobials and enable precise treatments tailored for each individual case, thereby reducing the spread of multi-drug resistance among microbial populations. A live/dead stain (e.g. viability dye) can also be incorporated in unused spectral channels, to distinguish single, living microorganisms which did not divide over the course of the assay from those that are dead.
In addition to antimicrobial susceptibility, other microbial phenotype measurements can be combined with HiPR-FISH species identification and quantification. In some embodiments, the tolerance or persistence of microbial cells in the presence of environmental stress can be determined by measuring the gene expression levels for stress response genes (e.g. RpoS, RpoN, and/or RpoE, which encodes the sigma factor that regulates the response to conditions of stress). In some embodiments, motility or chemotaxis measurements can be combined with HiPR-FISH to identify cellular motility in a taxa-specific fashion. In some embodiments, the production of reactive oxygen species (ROS), which play important roles in promoting microbial tolerance to environmental stress, can be measured and linked to the species identity of each cell. In some embodiments, the expression of Type 3 Secretion System (T3 SS) genes, which are used by certain pathogens to infect host cells and evade host immune response, can be measured and linked to species identity. In some embodiments, the expression of Type IV Secretion System (T4SS), which is related to the prokaryotic conjugation machinery and is involved in transport of proteins and DNA across the cell membrane, can be measured and linked to species identity. In some embodiments, the expression of quorum sensing genes, which are important in modulating collective behavior of communities containing many microbial cells, can be measured and linked to species identity. In some embodiments, the expression of genes related to biofilm formation can be measured and linked to species identity. In some embodiments, microbial cells can be subjected to a phage to identify phage-susceptible microbial species.
In some embodiments, the present disclosure is directed to a method that achieves high phylogenetic resolution by taking advantage of the abundance of existing ribosomal subunit sequence information, such as the 16S ribosomal RNA sequence information, and a highly multiplexed binary encoding scheme. In some embodiments, each taxon from a list of taxa of microorganisms is probed with a custom designed taxon-specific targeting sequence, flanked by a subset of n unique encoding sequences. In some embodiments, each taxon is assigned a unique n-bit binary word, where 1 or 0 at the ith bit indicates the taxon-specific targeting sequence is flanked or not flanked by the ih encoding sequence. In some embodiments, a mixture of n decoding probes, each complementary to one of the n encoding sequences and conjugated to a unique label, is allowed to hybridize to their complementary encoding sequences. In some embodiments, the spectrum of labels for each cell is then detected using spectral imaging techniques. In some embodiments, the barcode identity for each cell can then be assigned using a support vector machine, using spectra of cells encoded with known barcodes or using computationally simulated spectra as training data.
In some embodiments, each taxon from a list of taxa of microorganisms is assigned a unique n-bit binary code selected from a plurality of unique n-bit binary codes, where n is an integer greater than 1.
A “binary code” refers to a representation of taxa using a string made up of a plurality of “0” and “1” from the binary number system. The binary code is made up of a pattern of n binary digits (n-bits), where n is an integer representing the number of labels used. The bigger the number n, the greater number of taxa can be represented using the binary code. For example, a binary code of eight bits (an 8-bit binary code, using 8 different labels) can represent up to 255 (28−1) possible taxa. (One is subtracted from the total possible number of codes because no taxon is assigned a code of all zeros “00000000.” A code of all zeros would mean no decoding sequence, and thus no label, is attached. In other words, there are no non-labeled taxa.) Similarly, a binary code of ten bits (a 10-bit binary code) can represent up to 1023 (210−1) possible taxa. In some embodiments a binary code may be translated into and represented by a decimal number. For example, the 10-bit binary code “0001100001” can also be represented as the decimal number “97.”
Each digit in a unique binary code represents whether a readout probe and the fluorophore corresponding to that readout probe are present for the selected species. In some embodiments, each digit in the binary code corresponds to a Readout probe (from Readout probe 1 (R1) through Readout probe n (Rn) in an n-bit coding scheme). In a specific embodiment, the n is 10 and the digits of an n-bit code correspond to R1 through R10. In some embodiments, the fluorophores that correspond to R1 through Rn are determined arbitrarily. For example, if n is 10, R1 can correspond to an Alexa 488 fluorophore, R2 can correspond to an Alexa 546 fluorophore, R3 can correspond to a 6-ROX (6-Carboxy-X-Rhodamine, or Rhodamine Red X) fluorophore, R4 can correspond to a Pacific Green fluorophore, R5 can correspond to a Pacific Blue fluorophore, R6 can correspond to an Alexa 610 fluorophore, R7 can correspond to an Alexa 647 fluorophore, R8 can correspond to a DyLight-510-LS fluorophore, R9 can correspond to an Alexa 405 fluorophore, and R10 can correspond to an Alexa532 fluorophore. Other n-bit and readout probes combinations are also contemplated herein. In some embodiments, other fluorophores including, but not limited to Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Flourescein FITC, Alexa 430, R-phycoerythrin (PE), Tamara, Cy3.5 581, Rox, Alexa fluor 568, Red 613, Texas Red, Alexa fluor 594, Alexa fluor 633, Alexa fluor 660, Alexa fluor 680, Cy5, Cy 5.5, Cy 7, and Allophycocyanin are used in the n-bit encoding system.
In some embodiments, the n-bit binary code is between a 2-bit binary code and 50-bit binary code, a 2-bit binary code and 40-bit binary code, or 2-bit binary code and 30-bit binary code. In some embodiments, the n-bit binary code is selected from the group consisting of 2-bit binary code, 3-bit binary code, 4-bit binary code, 5-bit binary code, 6-bit binary code, 7-bit binary code, 8-bit binary code, 9-bit binary code, 10-bit binary-code, 11-bit binary code, 12-bit binary code, 13-bit binary code, 14-bit binary code, 15-bit binary code, 16-bit binary code, 17-bit binary code, 18-bit binary code, 19-bit binary code, 20-bit binary code, 21-bit binary code, 22-bit binary code, 23-bit binary code, 24-bit binary code, 25-bit binary code, 26-bit binary code, 27-bit binary code, 28 bit binary code, 29-bit binary code, 30-bit binary code, 31-bit binary code, 32-bit binary code, 33-bit binary code, 34-bit binary code, 35-bit binary code, 36-bit binary code, 37-bit binary code, 38 bit binary code, 39-bit binary code, 40-bit binary code, 41-bit binary code, 42-bit binary code, 43-bit binary code, 44-bit binary code, 45-bit binary code, 46-bit binary code, 47-bit binary code, 48 bit binary code, 49-bit binary code, and 50-bit binary code.
Encoding Probes
In some embodiments, the gene for a ribosomal subunit is used as a marker for phylogenetic placement. In some embodiments, 16S rRNA gene is used as a marker for phylogenetic placement. In some embodiments, methods of the present disclosure comprise multiplexed in-situ hybridization of encoding probes targeting taxon-specific segments of multiple unique 16S rRNA genes present in a microorganism population. In some embodiments, the 5S and/or 23S rRNA are used independently or in conjunction with 16S rRNA as a marker for phylogenetic placement. In some embodiments, if non-bacterial microorganisms are targeted, other rRNA may be targeted.
In some embodiments, a set of ending probes comprises subsets of encoding probes, wherein each subset targets a specific taxon. In some embodiments, a subset of encoding probes contains one unique targeting sequence specific to a taxon; that is, the encoding probes within a subset share a common targeting sequence specific to a taxon. In some embodiments, a subset of encoding probes contains multiple unique targeting sequences, each unique targeting sequence being specific to the same taxon as other targeting sequences within the same subset.
Targeting Sequences
In some embodiments, each encoding probe comprises a targeting sequence which is substantially complementary to a taxon-specific 16S rRNA sequence. By “substantially complementary” it is meant that the nucleic add fragment is capable of hybridizing to at least one nucleic acid strand or duplex even if less than all nucleobases base pair with a counterpart nucleobase. In certain embodiments, a “substantially complementary” nucleic add contains at least one sequence in which about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 77%, 8%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, to about 100%, and any range therein, of the nucleobase sequence is capable of basepairing with at least one single or double stranded nucleic acid molecule during hybridization.
In some embodiments, the targeting sequence is designed to have a predicted melting temperature of between about 45° C. and about 65° C. or between about 55° C. and about 65° C. As used herein, the term “about” refers to an approximately ±10% variation from a given value. In some embodiments, the predicted melting temperature of the targeting sequence is 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C. or 65° C. In some embodiments, the targeting sequence has a GC content of about 55%, 60%, 65% or 70%.
In some embodiments, the taxon-specific targeting sequence in an encoding probe is designed as follows. At first, 16S sequences from a plurality of microorganisms are grouped by taxon and sequence similarity and a consensus sequence is generated for each taxon. In some embodiments, a targeting sequence specific for a consensus sequence is at least 10 nucleotides to at least 100 nucleotides long. In some embodiments, a targeting sequence specific for a consensus sequence is at least 15 nucleotides long, at least 16 nucleotides long, at least 17 nucleotides long, at least 18 nucleotides long, at least 19 nucleotides long, at least 20 nucleotides long, at least 21 nucleotides long, at least 22 nucleotides long, at least 23 nucleotides long, at least 24 nucleotides long, at least 25 nucleotides long, at least 26 nucleotides long, at least 27 nucleotides long, at least 28 nucleotides long, at least 29 nucleotides long, at least 30 nucleotides long, at least 35 nucleotides long, at least 40 nucleotides long, at least 45 nucleotides long, or at least 50 nucleotides long. In some embodiments, the candidate targeting sequence is aligned against a catalog of all full-length 16S rRNA sequences of a list of microorganisms. In a specific embodiment, the alignment is performed using Blastn (NCBI). In a specific embodiment, the alignment is performed using BWA. In a specific embodiment, the alignment is performed using bowtie. In a specific embodiment, the alignment is performed using bowtie2. In some embodiments, a maximum continuous homology (MCH) score, defined as the maximum number of continuous bases that are shared between the query and the target sequence, is calculated for each blast hit. In some embodiments, only candidate targeting sequences having blast hits to the consensus sequence above a threshold MCH score are considered significant and used for further analysis. In some embodiments, a blast on-target rate, defined as the ratio between the number of correct blast hits and the total number of significant blast hits, is calculated for each candidate targeting sequence having a significant BLAST hit. In some embodiments, any candidate targeting sequence with a blast on-target rate of less than 1 is excluded from the probe set to avoid ambiguity, and the remaining candidate targeting sequences are used as targeting sequences in encoding probe synthesis.
In some embodiments, the targeting sequence of an encoding probe is designed using publicly-available 16S rRNA sequence data. In some embodiments, the targeting sequence of an encoding probe is designed using publicly-available 23S rRNA sequence data. In some embodiments, the targeting sequence of an encoding probe is designed using publicly-available 5S rRNA sequence data. In some embodiments, the targeting sequence of an encoding probe design is designed using custom catalogues of 16S rRNA sequences. In some embodiments, the targeting sequence of an encoding probe design is designed using custom catalogues of 23S rRNA sequences. In some embodiments, the targeting sequence of an encoding probe design is designed using custom catalogues of 5S rRNA sequences. In some embodiments, the targeting sequence of an encoding probe is designed using publicly-available 16S-5S rRNA sequence data. In some embodiments, the targeting sequence of an encoding probe is designed using publicly-available 16S-5S-23S rRNA sequence data. In some embodiments, the targeting sequence of an encoding probe design is designed using custom catalogues of 16S-5S rRNA sequences. In some embodiments, the targeting sequence of an encoding probe design is designed using custom catalogues of 16S-5S-23S rRNA sequences. In a specific embodiment, high-quality, full-length 16S sequences are obtained by circular consensus sequencing (SMRT-CCS). In a specific embodiment, high-quality, full-length 16S sequences are obtained by Nanopore sequencing.
In some embodiments, SMRT-CCS of a 16S ribosomal sequence involves isolating ribosomal DNA from a microorganism. In a specific embodiment, DNA isolation is achieved using QIAamp DNA Mini Kit. In a specific embodiment, DNA isolation is achieved using DNeasy PowerSoil Pro Kit. In some embodiments, ribosomal DNA is amplified using universal primers. In some embodiments, the amplified ribosomal DNA is purified, and sequenced. In a specific embodiment, sequencing is performed on a PacBio Sequel instrument. In a specific embodiment, sequencing is performed on a PacBio Sequel IIe instrument. In a specific embodiment, sequencing is performed on a Nanopore MinION instrument. In a specific embodiment, sequencing is performed on a Nanopore GridION instrument. In a specific embodiment, sequencing is performed on a Nanopore PromethION instrument. In some embodiments, sequence data is processed to create a circular consensus sequence with a threshold of 99% accuracy. In a specific embodiment, the sequence data processing is achieved using rDnaTools. In some embodiments, the circular consensus sequences are used for probe design. In some embodiments, to increase the sequence design space, and to improve identification of closely related species, the workflow uses a full 16S-23S rRNA region. In some embodiments, to increase the sequence design space, and to improve identification of closely related species, the workflow uses a full 16S-5S-23S rRNA region.
In some embodiments, the targeting sequence of an encoding probe is designed using a database that is relevant for a system. In a specific embodiment, the system is the gut microbiome. In some embodiments, the targeting sequence of an encoding probe is designed using a database that is relevant for a disease or infection.
Spacers
In some embodiments, a targeting sequence in an encoding probe is concatenated on both ends with 3 nucleotide (3-nt) spacers. In some embodiments, the 3-nt spacers comprise a random string of three nucleotides. In some embodiments, the 3-nt spacers are sequences designed from the 16S rRNA molecule, 5S rRNA molecule, or 23S rRNA molecule (i.e., three nucleotides upstream and downstream of the selected 16S targeting sequence is used as the 3-nt spacers). In some embodiments the spaces are non-nucleotide chemical spacers. Non-nucleotide chemical spacers include, but are not limited to, hexanediol, hexa-ethyleneglycol, or triethylene glycol spacers.
Readout Sequences
In some embodiments, a targeting sequence is concatenated to at least one readout sequence depending on the unique n-bit binary code assigned to the taxon that the targeting sequence is specific for. Each readout sequence is substantially complementary to the sequence of a corresponding labeled readout probe.
In some embodiments, a readout sequence is at least 15 nucleotides long, at least 16 nucleotides long, at least 17 nucleotides long, at least 18 nucleotides long, at least 19 nucleotides long, at least 20 nucleotides long, at least 21 nucleotides long, at least 22 nucleotides long, at least 23 nucleotides long, at least 24 nucleotides long, at least 25 nucleotides long, at least 26 nucleotides long, at least 27 nucleotides long, at least 28 nucleotides long, at least 29 nucleotides long, or at least 30 nucleotides long. In some embodiments, candidate readout sequences are blasted against a nucleotide database to ensure that they are not substantially complementary to regions of 16S ribosomal sequences.
Forward and Reverse Primers
In some embodiments, a targeting sequence is concatenated to a set of sequences (forward primer and reverse primer sequences) that are substantially complementary to primers that can be used to amplify the encoding probe in a polymerase chain reaction (PCR). In some embodiments, the forward and reverse primers are designed to have predicted melting temperatures of between about 55° C. and about 65° C. As used herein, the term “about” refers to an approximately ±10% variation from a given value. In some embodiments, the predicted melting temperature of the forward and reverse primers are 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C. or 65° C. In some embodiments, the forward and reverse primers have a GC content of about 55%, 60%, 65% or 70%.
In some embodiments, the set of forward and reverse primers are designed such that the set of forward and reverse primers are not substantially complementary to the targeting sequence or readout sequences. In some embodiments, the set of forward and reverse primers are designed such that the set of forward and reverse primers are not substantially complementary to any sequences that are substantially complementary to the targeting sequence or readout sequences. In a specific embodiment, the set of forward primer and reverse primer sequences comprise the nucleotide sequence CGATGCGCCAATTCCGGTTC (SEQ ID NO: 1808) and the nucleotide sequence GTCTATTTTCTTATCCGACG (SEQ ID NO: 1809).
In some embodiments, the forward primer or the reverse primer is at least 15 nucleotides long, at least 16 nucleotides long, at least 17 nucleotides long, at least 18 nucleotides long, at least 19 nucleotides long, at least 20 nucleotides long, at least 21 nucleotides long, at least 22 nucleotides long, at least 23 nucleotides long, at least 24 nucleotides long, at least 25 nucleotides long, at least 26 nucleotides long, at least 27 nucleotides long, at least 28 nucleotides long, at least 29 nucleotides long, or at least 30 nucleotides long.
Decoding Probes
In some embodiments, the present disclosure utilizes a set of n number of decoding probes representing an n-bit coding scheme where n is an integer. In some embodiments, each probe in the set of decoding probes corresponds to a digit in the plurality of unique n-bit binary codes.
In some embodiments, each probe in the set of decoding probes is conjugated with a label that provides a detectable signal.
In some embodiments, each probe in a set of decoding probes is labeled different from other probes in the set, and each decoding probe is substantially complementary to a corresponding readout sequence selected from a set of n number of readout sequences.
In some embodiments, the detectable signal is a cyanine dye (e.g., Cy2, Cy3, Cy3B, Cy5, Cy5.5, Cy7, etc.), Alexa Fluor dye, Atto dye, photo switchable dye, photoactivatable dye, fluorescent dye, metal nanoparticle, semiconductor nanoparticle or “quantum dots”, fluorescent protein such as GFP (Green Fluorescent Protein), or photoactivatable fluorescent protein, such as PAGFP, PSCFP, PSCFP2, Dendra, Dendra2, EosFP, tdEos, mEos2, mEos3, PAmCherry, PAtagRFP, mMaple, mMaple2, and mMaple3.
In a specific embodiment, the detectable signal is a fluorophore. In some embodiments, the detectable signal is a fluorophore that emits light in infrared or near-infrared. In a specific embodiment, the fluorophore is selected from the group consisting of Alexa 405, Pacific Blue, Pacific Green, Alexa 488, Alexa 532, Alexa 546, Rhodamine Red X, Alexa 610, Alexa 647, and DyLight-510-LS, Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Fluorescein FITC, Alexa 430, R-phycoerythrin (PE), Tamara, Cy3.5 581, Rox, Alexa fluor 568, Red 613, Texas Red, Alexa fluor 594, Alexa fluor 633, Alexa fluor 660, Alexa fluor 680, Cy5, Cy5.5, Cy7, Allophycocyanin, and ROX (carboxy-X-rhodamine). In some embodiments, the detectable signal is Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 561, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor 647-R-phycoerythrin, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 680-allophycocyanin, Alexa Fluor 700, Alexa Fluor 750, Alexa Fluor 790, Alexa Fluor Plus 405, Alexa Fluor Plus 488, Alexa Fluor Plus 555, Alexa Fluor Plus 594, Alexa Fluor Plus 647, Alexa Fluor Plus 680, Alexa Fluor Plus 750, Alexa Fluor Plus 800, Pacific Blue, Pacific Green, Rhodamine Red X, DyLight 485-LS, DyLight-510-LS, DyLight 515-LS, DyLight 521-LS, Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Fluorescein FITC, R-phycoerythrin (PE), Tamara, Cy3.5 581, ROX (carboxy-X-rhodamine), Red 613, Texas Red, Cy5, Cy5.5, Cy7, Allophycocyanin, ATTO 430LS, ATTO 490LS, ATTO 390, ATTO 425, Cyan 500 NHS-Ester, ATTO 465, ATTO 488, ATTO 495, ATTO Rho110, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 643, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740.
In some embodiments, a readout probe is at least 10 nucleotides long, at least 11 nucleotides long, at least 12 nucleotides long, at least 13 nucleotides long, at least 14 nucleotides long, at least 15 nucleotides long, at least 16 nucleotides long, at least 17 nucleotides long, at least 18 nucleotides long, at least 19 nucleotides long, at least 20 nucleotides long, at least 21 nucleotides long, at least 22 nucleotides long, at least 23 nucleotides long, at least 24 nucleotides long, at least 25 nucleotides long, at least 26 nucleotides long, at least 27 nucleotides long, at least 28 nucleotides long, at least 29 nucleotides long, or at least 30 nucleotides long.
Imaging
In some embodiments, the labels used in the present methods are imaged using a microscope. In some embodiments, the microscope is a confocal microscope. In some embodiments, the microscope is a fluorescence microscope. In some embodiments, the microscope is a light-sheet microscope. In some embodiments, the microscope is a super-resolution microscope.
Barcode Decoding
In some embodiments, a support vector machine is trained on reference data to predict the barcode of single cells in the synthetic communities and environmental samples. In a specific embodiment, the support vector machine is Support Vector Regression (SVR) from Python package. As used herein, the term “support-vector machine” (SVM) refers to a supervised learning model with associated learning algorithms that analyze data used for classification and regression analysis. Given a set of training examples, each marked as belonging to one or the other of two categories, an SVM training algorithm builds a model that assigns new examples to one category or the other, making it a non-probabilistic binary linear classifier. An SVM model is a representation of the examples as points in space, mapped so that the examples of the separate categories are divided by a clear gap that is as wide as possible. New examples are then mapped into that same space and predicted to belong to a category based on which side of the gap they fall.
In some embodiments, the reference spectra are obtained through a brute force approach involving the measurement of the spectra of all possible barcodes using barcoded test E. coli cells. In some embodiments, the n-bit binary encoding is a 10-bit binary encoding and tire reference spectra are obtained through measuring 1023 reference spectra.
In some embodiments the reference spectra are obtained by simulation of all possible spectra. In some embodiments, the simulated spectral data can be used as reference examples for the support vector machine. In some embodiments, the spectra corresponding to individual n-bit binary codes are simulated by adding together the measured spectra of each individual fluorophore (e.g., the reference spectrum for 0000010011 is generated by adding the spectra of R1, R2, and R5; or the reference spectrum for 1010010100 is generated by adding the spectra of R3, R5, R8 and R10). In some embodiments, the spectra corresponding to individual n-bit binary codes are simulated by adding the measured spectra of each individual fluorophore weighted by the relative contribution to the emission signal of each fluorophore. In some embodiments, the relative contribution of each fluorophore is calculated using a Forster Resonant Energy Transfer (FRET) model.
In one aspect, the disclosure is directed to a computer-readable storage device storing computer readable instructions, which when executed by a processor causes the processor to assign each taxon in a list of taxa of microorganisms a unique n-bit binary code selected from a plurality of unique n-bit binary codes, and design decoding and encoding probes suitable for use in such n-bit binary coding scheme.
The phrase “computer-readable storage device” refers to a computer readable storage device or a computer readable signal medium. A computer-readable storage device, may be, for example, a magnetic, optical, electronic, electromagnetic, infrared, or semiconductor system, apparatus, or device, or any suitable combination of the foregoing; however, the computer readable storage device is not limited to these examples except a computer readable storage device excludes computer readable signal medium Additional examples of the computer readable storage device can include: a portable computer diskette, a hard disk, a magnetic storage device, a portable compact disc read-only memory (CD-ROM), a random access memory' (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical storage device, or any appropriate combination of the foregoing; however, the computer readable storage device is also not limited to these examples.
Any tangible medium that can contain, or store, a program for use by or in connection with an instruction execution system, apparatus, or device could be a computer readable storage device.
A computer readable signal medium may include a propagated data signal with computer readable program code embodied therein, such as, but not limited to, in baseband or as part of a carrier wave. A propagated signal may take any of a plurality of forms, including, but not limited to, electro-magnetic, optical, or any suitable combination thereof. A computer readable signal medium may be any computer readable medium (exclusive of computer readable storage device) that can communicate, propagate, or transport a program for use by or in connection with a system, apparatus, or device. Program code embodied on a computer readable signal medium may be transmitted using any appropriate medium, including but not limited to wireless, wired, optical fiber cable, RF, etc., or any suitable combination of the foregoing. The term “memory” as used herein comprises program memory' and working memory. The program memory may have one or more programs or software modules. The working memory stores data or information used by the CPU in executing the functionality described herein.
The term “processor” may include a single core processor, a multi-core processor, multiple processors located in a single device, or multiple processors in wired or wireless communication with each other and distributed over a network of devices, the Internet, or the cloud. Accordingly, as used herein, functions, features or instructions performed or configured to be performed by a “processor”, may include the performance of the functions, features or instructions by a single core processor, may include performance of the functions, features or instructions collectively or collaboratively by multiple cores of a multi-core processor, or may include performance of the functions, features or instructions collectively or collaboratively by multiple processors, where each processor or core is not required to perform every function, feature or instruction individually. The processor may be a CPU (central processing unit). The processor may comprise other types of processors such as a GPU (graphical processing unit). In other aspects of the disclosure, instead of or in addition to a CPU executing instructions that are programmed in the program memory, the processor may be an ASIC (application-specific integrated circuit), analog circuit or other functional logic, such as a FPGA (field-programmable gate array), PAL (Phase Alternating Line) or PLA (programmable logic array).
The CPU is configured to execute programs (also described herein as modules or instructions) stored in a program memory to perform the functionality described herein. The memory may be, but not limited to, RAM (random access memory), ROM (read only memory) and persistent storage. The memory is any piece of hardware that is capable of storing information, such as, for example without limitation, data, programs, instructions, program code, and/or other suitable information, either on a temporary basis and/or a permanent basis.
In some embodiments, a computer-readable storage device comprises instructions for assigning each taxon in a list of taxa of microorganisms a unique n-bit binary code selected from a plurality of unique n-bit binary codes; designing a set of n number of decoding probes, wherein each decoding probe corresponds to a digit in the n-bit binary code, and where each decoding probe is substantially complementary to a readout sequence selected from a set of n number of readout sequences, and designing a set of encoding probes, where the set of encoding probes includes a plurality of subsets of encoding probes, wherein each encoding probe comprises a targeting sequence and one or more readout sequences, the encoding probes within each subset comprise a targeting sequence that is specific to a taxon in tire list of taxa of microorganisms and is different from a targeting sequence of the encoding probes of another subset, and the readout sequences in the encoding probes within a subset are selected from the set of n number of readout sequences based on the unique n-bit binary code assigned to the taxon which the targeting sequence of the subset is specific to.
In some embodiments, the computer-readable storage device comprises instructions for designing encoding probes of a subset, wherein the targeting sequence in the encoding probes of a subset is substantially complementary to a consensus 16S ribosomal sequence specific to a taxon. In some embodiments, the computer-readable storage device comprises instructions for designing encoding probes of a subset, wherein the targeting sequence in the encoding probes of a subset is substantially complementary to a consensus 5S ribosomal sequence specific to a taxon. In some embodiments, the computer-readable storage device comprises instructions for designing encoding probes of a subset, wherein the targeting sequence in the encoding probes of a subset is substantially complementary to a consensus 23S ribosomal sequence specific to a taxon. In some embodiments, the computer-readable storage device comprises instructions for designing encoding probes of a subset, wherein the targeting sequence in the encoding probes of a subset is substantially complementary to a consensus 16S-5S ribosomal sequence specific to a taxon. In some embodiments, the computer-readable storage device comprises instructions for designing encoding probes of a subset, wherein the targeting sequence in the encoding probes of a subset is substantially complementary to a consensus 16S-5S-23S ribosomal sequence specific to a taxon. In some embodiments, the computer-readable storage device comprises instructions for designing encoding probes of a subset, wherein the targeting sequence in the encoding probes of a subset is substantially complementary to a consensus 16S-23S ribosomal sequence specific to a taxon. In some embodiments, the targeting sequence is blasted against a nucleotide database to ensure that the target sequence is not substantially complementary to any sequence other than the consensus 16S ribosomal sequence to which the target sequence is specific.
In some embodiments, a set of encoding probes comprises subsets of encoding probes, wherein each subset targets a specific taxon. In some embodiments, a subset of encoding probes contains one unique targeting sequence specific to a taxon; that is, the encoding probes within a subset share a common targeting sequence specific to a taxon. In some embodiments, a subset of encoding probes contains multiple unique targeting sequences, each unique targeting sequence being specific to the same taxon as other targeting sequences within the same subset.
In some embodiments, the microbial cell in the sample is identified and characterized directly from the sample. In some embodiments, the microbial cell in the sample is identified and characterized after culturing. In some embodiments, the microbial cell in the sample is cultured for numerous cell divisions. A skilled artisan would readily recognize that the number of cell divisions depends on the species doubling time, which varies from species to species. In some embodiments, the microbial cell in the sample is cultured for one to numerous cell divisions. In some embodiments, the microbial cell in the sample is cultured for less than one division cycle. In some embodiments, the microbial cell in the sample is cultured for very few cell division cycles. In some embodiments, the microbial cell in the sample is cultured for about 1 to about 12 cell division cycles. In some embodiments, the microbial cell in the sample is cultured for about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 cell division cycles. In some embodiments, the microbial cell in the sample is cultured for about 1 minute to about 12 hours. In some embodiments, the microbial cell in the sample is cultured for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 15 minutes, about 16 minutes, about 17 minutes, about 18 minutes, about 19 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 80 minutes, about 90 minutes, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, or about 12 hours.
To enable rapid antimicrobial resistance profiling, the present methods combine fluorescence in situ hybridization to enable the first hybrid measurements of antimicrobial resistance (
One or more microbes in a specimen can be directly inoculated onto a device with patterned compartments. The testing can proceed with or without further culturing. In scenarios where the sample is not subjected to culturing, species identification FISH methods, such as HiPR-FISH, and single-molecule FISH to simultaneously image the species identity is combined with analysis regarding the presence or absence of one or more antimicrobial genes and metabolites, proteins, carbohydrates, and/or lipids in the same cells. This approach will enable a paired readout of microbial species identity and antimicrobial susceptibility. In situations where phenotypic readout of antimicrobial susceptibility is desired, the compartments will be filled with a culturing media containing an antimicrobial drug at a known concentration. An initial image will be taken to record the number of cells in each compartment of the device. The microbes are allowed to replicate for a defined period of time (minutes to a few hours). After the growth period, another image or measurement will be taken to record cellular state in each compartment of the device after the growth period and look for the presence of genes and metabolites, proteins, carbohydrates, and/or lipids that are known to confer antimicrobial resistance. The cellular state can potentially be read out in a few different ways. For example, cellular state can be measured simply by counting the number of cells in each compartment. Cell growth can also be measured by probing the metabolic product concentration in the solution such as dissolved CO2 or measuring the amount of heat dissipation using calorimetry techniques. Cellular state can also be inferred by measuring the abundance of expressed metabolic genes or stress response genes using single-molecule fluorescence in situ hybridization. Cellular state may also be measured using a simple live/dead stain. After cellular state measurement, the identity of the cells will subsequently be read out using multiplexed fluorescence in situ hybridization (e.g. HiPR-FISH) (
In some aspects, the present disclosure provides methods determining the susceptibility (or resistance) of the microbial cells in the sample to one or more antimicrobial agents. In some aspects, the present disclosure provides methods of identifying microbial cells in a sample in parallel with determination of the microbial cells in the sample susceptibility to one or more antimicrobial agents. As used herein, a microbial cell is “susceptible” to an antimicrobial when it is inhibited by the usually achievable concentration of the antimicrobial agent when the dosage recommended to treat the site of infection is used. Further, as used herein, a microbial cell is “resistant” to an antimicrobial when it is not inhibited by the usually achievable concentration of an antimicrobial agent with normal dosage schedules and/or that has a minimum inhibitory concentration that falls in the range in which specific microbial resistance mechanisms are likely.
In some embodiments, the microbial cells in a sample are exposed to different concentrations to determine the minimum inhibitory concentration of the antimicrobial agent. In some embodiments, the minimum inhibitory concentration (MIC) of the antimicrobial agent for the microbial cell in the sample is greater than the MIC of a typical microbial cell of the same strain. In some embodiments, the minimum inhibitory concentration (MIC) of the antimicrobial agent for the microbial cell in the sample is lower than the MIC of a typical microbial cell of the same strain.
In some embodiments, the microbial cells in the sample are exposed to one or more antimicrobial agents in a concentration range of about 2-fold to about 500-fold of the MIC of a typical microbial cell of the same strain. In some embodiments, the microbial cells in the sample are exposed to one or more antimicrobial agents in a concentration range of about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 11-fold, about 12-fold, about 13-fold, about 14-fold, about 15-fold, about 16-fold, about 17-fold, about 18-fold, about 19-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, about 100-fold, about 150-fold, about 200-fold, about 250-fold, about 300-fold, about 350-fold, about 400-fold, about 450-fold, or about 500-fold of the MIC of a typical microbial cell of the same strain.
Any appropriate antimicrobial agent effective against a microbial cell disclosed herein may be used in the methods of the present disclosure. In some embodiments, the one or more antimicrobial agents include, but are not limited to rifamycins, rifampicin, aminoglycosides, fluoroquinolones, penicillins, carbapenems, cephalosporins antibiotic, penicillinase-resistant penicillins, aminopenicillins, β-lactams, tetracyclines, sulfonamides, phenicols, trimethoprim, macrolides, fosfomycin, erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, synthetic drugs quinolones, sulfonamides, trimethoprim, sulfamethoxazole, streptomycin, glycopeptides, glycylcyclines, ketolides, lipopeptides, monobactams, nitroimidazoles, oxazolidinones, polymixins, benzilpenicilline, aminoglycosides, amikacin, arbekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin, tobramycin, apramycin, amphotericin, nystatin, pimaricin, fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, ketoconazole, echinocandins, polyenes, allylamines, naftifine, terbinafine, morpholines, amorolfine, 5-fluorocytosine, atovaquone/proguanil, malarone, chloroquine, doxycycline, mefloquine, primaquine, meropenem, and tafenoquine.
In some embodiments, survival, growth or development of the microbial cell in a sample is determined by counting the number of cells observed. In some embodiments, survival, growth or development of the microbial cell in a sample is determined by counting the number of cells observed relative to unperturbed wells. In some embodiments, survival, growth or development of the microbial cell in a sample is determined by measuring cell metabolism. In some embodiments, growth or development of the microbial cell in a sample is determined by measuring cell metabolism at varying concentrations of one or more antimicrobial agents. In some embodiments, metabolic measurements include, but are not limited to, concentration of dissolved carbon dioxide, heat dissipation, oxygen consumption, expressed genes involved in cell homeostasis, stress response, division, and/or growth, and/or cell membrane integrity, and/or cell wall integrity, and/or S-layer integrity (live/dead stain).
To enable prediction of antimicrobial resistance in the future, HiPR-FISH can be applied to not only measure the microbial identity via the rRNA sequences, but also measure the presence of antimicrobial genes, proteins, or metabolic products. To measure the presence of antimicrobial genes, panels of probes that are specific and only specific to a list of antimicrobial genes are designed. These probes are similarly encoded into binary barcodes by adding flanking sequences to the encoding sequences. These flanking sequences may be readout sequences or sequences for additional signal amplification. In the case where the flanking sequences are readout sequences, the specimen can be hybridized with readout probes and imaged on an imaging device. In the case where the flanking sequences are initiator sequences, the specimen is subjected to a round of signal amplification using amplifier probes. The amplifier probes may be conjugated with fluorophores. If the amplifier probes are already conjugated with fluorophores, the specimen can be imaged on an imaging device after amplification hybridization. If the amplifiers are not conjugated with fluorophores, the amplifier probes will contain a readout sequence. The amplified specimen is then hybridized with fluorescently labeled readout probes before being imaged on an imaging device. To measure the presence of antimicrobial proteins, antibodies conjugated with DNA readout sequences are engineered. The DNA barcoded antibodies will bind to proteins of interest, and the labeled specimen will be hybridized with fluorescently labeled readout probes before being imaged on an imaging device. To measure metabolic products such as sugars or lipids, DNA barcodes will be conjugated to molecules that bind specifically to the sugars or lipids of interest. The labeled specimen will then be hybridized with fluorescently labeled readout probes before being imaged on an imaging device. For measurement of proteins, sugars, and/or lipids, amplifier probes may also be used in a similar fashion as described for gene targets to increase signal and reduce the influence of noise. Examples of imaging devices include, but are not limited to, epifluorescent microscopes, confocal microscopes, multi-photon microscopes, and light-sheet microscopes.
Any number of genetic changes can affect the susceptibility of an organism to an antimicrobial agent or drug. For example, permeability changes in the bacterial cell wall can restrict antimicrobial access to target sites, changes in pumps can alter the efflux of the antimicrobial from the cell, proteins may enzymatically modify or degrade the antimicrobial agent, the cell may acquire an alternative metabolic pathway to that inhibited by the antimicrobial agent, the target of the antimicrobial agent may be modified, or the target enzyme may be overproduced.
In some embodiments, the present methods detect mutations that influence the development of antimicrobial resistance or susceptibility, such as nucleotide substitutions in the 23S rRNA gene that cause macrolide resistance, single nucleotide polymorphisms in ribosomal proteins such as L4 or L22, mutations within the rpsL gene, or frame shift mutation in ddl gene encoding a cytoplasm enzyme D-Ala-D-Ala ligase.
In some embodiments, the present methods can identify genetic changes in the microorganism compared to unmodified microorganisms of the same type. In some embodiments, the present methods identify deletions, duplications, single nucleotide polymorphisms (SNPs), frame-shift mutations, inversions, insertions, and/or substitutions associated with the development of susceptibility or resistance to a given antimicrobial agent. In some embodiments, the present methods identify mutations associated with increased drug resistance in genes including, but not limited to, genes encoding multidrug resistance proteins (e.g. PDR1, PDR3, PDR7, PDR9), ABC transporters (e.g. SNQ2, STE6, PDR5, PDR10, PDR11, YOR1), membrane associated transporters (GAS1, D4405), soluble proteins (e.g. G3PD), RNA polymerase, rpoB, gyrA, gyrB, 16S RNA, 23S rRNA, NADPH nitroreductase, sul2, strAB, tetAR, aac3-iid, aph, sph, cmy-2, floR, tetB, aadA, aac3-VIa, and sul1.
In some aspects, the present disclosure provides methods for identifying and characterizing an infectious microorganism such as a virus, bacterium, parasite, or fungus. The infectious microorganism can be a microorganism that causes infections in a human or an animal such as a species of livestock, poultry, and fish.
In some embodiments, the list of phyla of microorganisms include phyla Actinobacteria, Aquiflcae, Armatimonadetes, Bacteroidetes, Chlamydiae, Chlorobi, Chloroflexi, Chrysiogenetes, Cyanobacteria, Chrysiogenetes, Deferribacteres, Deinococcus-thermus, Dictyoglomi, Elusimicrobia, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes, Lentisphaerae, Nitrospirae, Planctomycetes, Proteobacteria, Spirochaetia, Synergistetes, Thermodesulfobacteria, Thermotogae, and Verrucomicrobia.
In some embodiments, the present disclosure provides methods for identifying and characterizing a virus including but not limited to, bacteriophage, RNA bacteriophage (e.g. MS2, AP205, PP7 and Qβ), Helicobacter pylori, infectious haematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Measles virus, Mumps virus, Rubella virus, Human Immunodeficiency Virus (HIV), Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, Norovirus, Zika Virus, Dengue Virus, Rabies Virus, Newcastle Disease Virus, and White Spot Syndrome Virus. In some embodiments, the methods identify and characterize a cell (e.g. human cell) infected with a virus of the disclosure.
In some embodiments, the present disclosure provides methods for identifying and characterizing a bacterium including but not limited to, Mycobacterium, Streptococcus, Staphylococcus, Shigella, Campylobacter, Salmonella, Clostridium, Corynebacterium, Pseudomonas, Neisseria, Listeria, Vibrio, Bordetella, E. coli (including pathogenic E. coli), Pseudomonas aeruginosa, Enterobacter cloacae, Mycobacterium tuberculosis, Staphylococcus aureus, Helicobacter pylori, and Legionella. In some embodiments, the present disclosure provides methods for identifying and characterizing a bacterium including, but not limited to, Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus saprophyticus, Streptococcus agalactiae, or a combination thereof.
In some embodiments, the present disclosure provides methods for identifying and characterizing a parasite including but not limited to, Plasmodium (i.e. P. falciparum, P. malariae, P. ovale, P. knowlesi, and P. vivax), Trypanosoma, Toxoplasma, Giardia, and Leishmania, Cryptosporidium, helminthic parasites: Trichuris spp. (whipworms), Enterobius spp. (pinworms), Ascaris spp. (roundworms), Ancylostoma spp. and Necator spp. (hookworms), Strongyloides spp. (threadworms), Dracunculus spp. (Guinea worms), Onchocerca spp. and Wuchereria spp. (filarial worms), Taenia spp., Echinococcus spp., and Diphyllobothrium spp. (human and animal cestodes), Fasciola spp. (liver flukes) and Schistosoma spp. (blood flukes).
In some embodiments, the present disclosure provides methods for identifying and characterizing a fungus including but not limited to, Aspergillus, Candida, Blastomyces, Coccidioides, Cryptococcus, Pneumocystis, Mucor, Rhizopus, Rhizomucor, Fusarium, Scedosporium, and Histoplasma.
Another aspect of the disclosure is directed to kits that allow practicing the methods of the present disclosure.
In some embodiments, the disclosure is directed to a kit which includes a list of taxa of microorganisms, wherein each taxon is assigned a unique n-bit binary code selected from a plurality of unique n-bit binary codes, wherein n is an integer greater than 1; a set of n number of decoding probes, wherein each decoding probe corresponds to a digit in the plurality of unique n-bit binary codes, is conjugated with a label that provides a detectable signal, wherein the labels on the decoding probes are different from each other, and is substantially complementary to a readout sequence selected from a set of n number of readout sequences; and instructions on how to design a set of encoding probes, wherein the set of encoding probes includes a plurality of subsets of encoding probes, wherein each encoding probe comprises a targeting sequence and one or more readout sequences, the encoding probes within each subset comprise a targeting sequence that is specific to a taxon in the list of taxa of microorganisms and is different from a targeting sequence of the encoding probes of another subset, and the readout sequences in the encoding probes within a subset are selected from the set of n number of readout sequences based on the unique n-bit binary code assigned to the taxon which the targeting sequence of the subset is specific to.
In some embodiments, the encoding probes within each subset comprise at least one targeting sequence that is specific to a taxon. In some embodiments, the encoding probes within each subset comprise at least two targeting sequences that are specific to the same taxon.
In some embodiments, the kit includes a device to practice the methods of the present disclosure. In some embodiments, the device is a multiwell platform. In some embodiments, the multiwell platform contains between 2 and 400 well, or 2 and 384 well, or 8 and 100 well. In some embodiments, the multiwell platform contains 2 wells, 3 wells, 4 wells, 5 wells, 6 wells, 7 wells, 8 wells, 9 wells, 10 wells, 12 wells, 24 wells, 25 wells, 30 wells, 48 wells, 50 wells, 75 wells, 96 wells, 100 wells, 150 wells, 200 wells, 250 wells, 300 wells, 350 wells, 384 wells, or 400 wells. In some embodiments, the wells contain drug-inoculated or drug-free agar, agarose, polyethylene glycol, or polyacrylamide. In some embodiments, the devices are a single or a double layer of silicon. In some embodiments, a plastic flow chamber is attached for HiPR-FISH processing and readout.
The methods disclosed herein can be performed directly in a biological sample, without the need to isolate and culture microorganisms. In some embodiments, the biological sample is a biological fluid or a tissue sample. In some embodiments, the biological sample includes, but is not limited to, bronchoalveolar lavage fluid (BAL), blood, serum, plasma, urine, cerebrospinal fluid, pleural fluid, synovial fluid, ocular fluid, peritoneal fluid, amniotic fluid, gastric fluid, lymph fluid, interstitial fluid, tissue homogenate, cell extracts, saliva, sputum, stool, physiological secretions, tears, mucus, sweat, milk, semen, seminal fluid, vaginal secretions, fluid from ulcers and other surface eruptions, blisters, and abscesses, and extracts of tissues associated with medical implants, and extracts of tissues including biopsies of normal, malignant, and suspect tissues or any other constituents of the body which may contain the microorganism of interest. In some embodiments, the sample is a human oral microbiome sample. In some embodiments, the sample is a whole organism.
In some embodiments, the sample is obtained from a patient diagnosed with, or suspected to be suffering from an infection, disease, or disorder. In some embodiments, the patient has been diagnosed with, or is suspected to be suffering from a bacterial, viral, fungal, or parasitic infection. In some embodiments, the infection includes, but is not limited to, tetanus, diphtheria, pertussis, pneumonia, meningitis, campylobacteriosis, mumps, measles, rubella, polio, flu, hepatitis, chickenpox, malaria, toxoplasmosis, giardiasis, or leishmaniasis.
In some embodiments, the patient has been diagnosed with, or is suspected to be suffering from an infection caused by a bacterium selected from the group consisting of: Mycobacterium, Streptococcus, Staphylococcus, Shigella, Campylobacter, Salmonella, Clostridium, Corynebacterium, Pseudomonas, Neisseria, Listeria, Vibrio, Bordetella, Helicobacter pylori, and Legionella.
In some embodiments, the patient has been diagnosed with, or is suspected to be suffering from an infection caused by a virus selected from the group consisting of: bacteriophage, RNA bacteriophage (e.g. MS2, AP205, PP7 and Qβ), Infectious Haematopoietic Necrosis Virus, Parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Measles virus, Mumps virus, Rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, and Poliovirus, Norovirus, Zika virus, Dengue Virus, Rabies Virus, Newcastle Disease Virus, and White Spot Syndrome Virus.
In some embodiments, the patient has been diagnosed with, or is suspected to be suffering from an infection caused by a parasite selected from the group consisting of: Plasmodium, Trypanosoma, Toxoplasma, Giardia, Leishmania, Cryptosporidium, helminthic parasites: Trichuris spp., Enterobius spp., Ascaris spp., Ancylostoma spp. and Necator spp., Strongyloides spp., Dracunculus spp., Onchocerca spp. and Wuchereria spp., Taenia spp., Echinococcus spp., and Diphyllobothrium spp., Fasciola spp., and Schistosoma spp.
Another aspect of the disclosure is directed to a method of analyzing a sample by performing multiple imaging rounds exchanging emissive readout probes which are referred to herein as HiPR-Swap.
HiPR-Swap is motivated by a need to target hundreds of thousands of rRNA, mRNA, and other molecules in the microbiomes and the host tissue in order to describe host-microbiome interactions. For example, to image on average 100 unique mRNAs in roughly 1000 taxa in the gut microbiome, along with all mammalian host transcripts would require us to be able to uniquely barcode ˜150,000 targets.
Several FISH-based methods use multiple rounds of imaging to achieve high multiplexity in their assays. Multiple rounds can be performed by: (1) photobleaching fluorescent probes before applying a next round of fluorescent probes; (2) applying DNAse to the specimen to degrade fluorescent probes before applying a next round of fluorescent probes; (3) adding photocleavable or chemically-cleavable linker molecules to the fluorescent probes, and performing the cleavage to remove fluorescence signal before applying a next round of fluorescent probes; (4) stripping probes using washes with high (>50%) formamide concentrations and/or low salt (≤2×SSC) and/or high temperatures (≥37° C.). These methods, however, are undesirable for a multitude of reasons, for example, they can be time consuming and have potential for photodamage. They can also be detrimental to sample integrity, are cost-prohibitive at scale, and possibly chemically incompatible. In addition, some can remove encoding probes necessary to conduct FISH-based methods. To overcome these deficiencies, the present disclosure uses DNA exchange as a method to quickly, specifically, carefully replace HiPR-FISH readout probes without disturbing encoding and/or amplifier probes. This method is referred to as HiPR-Swap.
High Phylogenetic Resolution microbiome mapping by Fluorescence in situ Hybridization (HiPR-FISH), is a versatile technology that uses binary encoding, spectral imaging, and machine learning based decoding to create micron-scale maps of the locations and identities of hundreds of microbial species in complex communities. See, for example, Shi, H. et al. “Highly multiplexed spatial mapping of microbial communities.” Nature vol. 588, 7839 (2020): 676-681 and PCT Patent Publication WO 2019/173555, filed Mar. 7, 2019. The contents of the aforementioned disclosures are each incorporated herein by reference in their entireties.
In the HiPR-Swap method, readout and encoding probes are designed such that the “landing pad” (the region on the encoding probe to which the readout probe binds) is shorter than or equal to in length to the readout probe. The landing pad being shorter than the readout probe creates a single-stranded overhang of the readout probe, as it extends past the end of the landing pad. The bigger the difference in length, the faster the exchange happens but there is also the risk of having a less stable readout probe being on the landing pad. Accordingly, there is a balance that needs to be struck to achieve a complete hybridization/exchange. In some instances, when the readout probe is of the same length as the landing pad, using a high concentration of exchange probes can result in a complete swap.
After a readout probe is bound, an exchange probe can be added to the specimen. The exchange probe can be constructed to be of equal length and a perfect reverse complement to the readout probe. In some instances, the exchange probe may contain locked nucleic acids to increase the stability of the exchange-readout pair. When added, the exchange probe seeds a hybridization to the exposed area of the readout probe. Over a short period of time the exchange probe completely hybridizes to the readout probe, thereby removing it from the encoding probe where it can be washed away. Importantly, orthogonal readout and exchange probes can be added simultaneously to reduce assay time.
Accordingly, a method for analyzing a sample can include:
In some embodiments, more than one type of probe set (e.g., encoding probe, emissive readout probes, and exchange probes) may be introduced to a sample. For example, there may be from at least 2 to at least 1 billion distinguishable probe sets that are introduced to a sample. In some embodiments, at least 2, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 300, at least 1,000, at least 3,000, at least 10,000, at least 30,000, at least 100,000, at least 500,000, or at least 1,000,000, at least 10,000,000, at least 50,000,000, at least 100,000,000, at least 500,000,000, or at least 1,000,000,000 distinguishable probe sets that are introduced to a sample. In some embodiments, the distinct probes are introduced simultaneously. In some embodiments, the distinct probes are introduced sequentially. In some embodiments, more than one type of probe set may be introduced to a sample over multiple rounds, with each round having multiple probe pools.
In the methods described herein for analyzing a sample, the method can include contacting at least one encoding probe with the sample to produce a first complex, wherein each encoding probe includes a targeting sequence, a first landing pad sequence, and a second landing pad sequence. This step may also be referred to as the “encoding probe hybridization” step. In here, at least one encoding probe is contacted with the sample to produce a first complex. The first complex can include the targeting sequence of the encoding probe hybridized to the nucleic acid target sequence.
In some embodiments, contacting the encoding probes with the sample is contacting the encoding probes with at least one nucleotide sequence of the sample. In some embodiments, contacting the encoding probes with the sample is hybridizing the encoding probe (e.g., via the targeting sequence present in the encoding probe) with a target sequence present in the sample.
In some embodiments, in order to contact encoding probes with the sample, the sample can be digested or lysed so as to allow the encoding probes (and other probes described herein) to contact with the target sequence.
In some embodiments, to contact the at least one encoding probe with the sample to produce a first complex, encoding buffer is added to the sample. In some embodiments, a pre-hybridization step can be performed prior to adding the encoding probe. In some embodiments, the encoding buffer can be added to the sample without the encoding probe. In some embodiments, the encoding buffer can be added to the sample about 30 minutes prior to adding the encoding probe.
In some embodiments, the encoding buffer can include a denaturing/deionizing agent, a salt buffer, a detergent, a polyanionic polymer, a blocking agent, acids, or combinations thereof. In some embodiments, the encoding buffer can include more than one type of agent, for example, the encoding buffer can include two or more polyanionic polymers and/or two or more blocking agents. In some embodiments, the encoding buffer can include a denaturing/deionizing agent, a salt buffer, a detergent, two polyanionic polymers, two blocking agents, and an acid.
In some embodiments, the encoding buffer can include a denaturing/deionizing agent. In some embodiments, the denaturing/deionizing agent can be formamide, ethylene carbonate, or urea. In some embodiments, the encoding buffer can include about 10% (v/v) to about 50% (v/v), about 15% (v/v) to about 45% (v/v), about 20% (v/v) to about 40% (v/v), about 25% (v/v) to about 35% (v/v), about 10% (v/v), 15% (v/v), 20% (v/v), 25% (v/v), or 30% (v/v) of a denaturing/deionizing agent (e.g., ethylene carbonate).
In some embodiments, the encoding buffer can include a salt buffer. In some embodiments, the salt buffer is saline sodium citrate (SSC), NaCl, or MgCl2. In some embodiments, the encoding buffer can include about 2× to about 20×, about 5× to about 10×, or about 5× of a salt buffer (e.g., saline sodium citrate (SSC)).
In some embodiments, the encoding buffer can include at least one polyanionic polymer. In some embodiments, the encoding buffer can include one polyanionic polymer. In some embodiments, the encoding buffer can include two polyanionic polymers. In some embodiments, the polyanionic polymer can be dextran sulfate, heparin, or polyglutamic acid. In some embodiments, the encoding buffer can include about 2.5% (v/v) to about 25% (v/v), about 5% (v/v) to about 15% (v/v), about 7.5% (v/v) to about 12.5% (v/v), about 5% (v/v), or about 10% (v/v) of a polyanionic polymer (e.g., dextran sulfate). In some embodiments, the encoding buffer can include about 20 μg/mL to about 80 μg/mL, about 30 μg/mL to about 70 μg/mL, about 40 μg/mL to about 60 μg/mL, or about 50 μg/mL of a polyanionic polymer (e.g., heparin).
In some embodiments, the encoding buffer can include a detergent. In some embodiments, the detergent can be Tween 20, Tween 80, sodium dodecyl sulfate (SDS), Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58. N-Dodecyl-beta-maltoside, Octyl-beta-glucoside, octylthioglucoside (OTG). In some embodiments, the encoding buffer can include about 0.01% (v/v) to about 1.0% (v/v), about 0.05% (v/v) to about 0.5% (v/v), or about 0.1% (v/v), or about 0.05% (v/v) of detergent (e.g., SDS).
In some embodiments, the encoding buffer can include an acid. In these embodiments, the acid lowers the pH of the buffer. In some embodiments, the acid can be citric acid. In some embodiments, the encoding buffer can include about 1 mM to about 30 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 7 mM to about 10 mM, or about 9 mM of an acid (e.g., citric acid).
In some embodiments, the encoding buffer can include at least one blocking agent. In some embodiments, the encoding buffer can include one blocking agent. In some embodiments, the blocking agents can be Denhardt's solution, bovine serum albumin (BSA), salmon sperm DNA, Ficoll, polyvinyl pyrrolidone (PVP), E. coli tRNA, casein solution, or random hexamers. In some embodiments, the encoding buffer can include about 0.1× to about 10×, about 0.5× to about 5×, about 1× to about 2×, or about 1× of a blocking agent (e.g., Denhardt's solution).
In some embodiments, the encoding buffer can include ethylene carbonate, dextran sulfate, SSC, Denhardt's solution, and SDS. In some embodiments, the encoding buffer can include 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, and 0.01% SDS.
Following the hybridization of the encoding probe with the target sequence to form a first complex, at least one first emissive readout probe is added to the first complex, wherein the first emissive readout probe comprises a label and a sequence complementary to the first landing pad sequence. In some embodiments, this step may be referred to as the “readout probe hybridization” step. In here, the emissive readout probes hybridize to their complementary sequences present in the first complex (e.g., first landing pad sequence).
In some embodiments, the encoding probe and the readout probe hybridization occur in the same step. In some embodiments, the readout probe hybridization is performed in the presence of the encoding buffer described above. In some embodiments, the encoding probe hybridization step, the readout probe hybridization step, and the readout step can occur sequentially or substantially in the same step.
In some embodiments, to hybridize the readout probes to the first complex, readout buffer is added to the sample. In some embodiments, to image the readout probes, a wash buffer is added to the sample.
In some embodiments, the wash buffer can include a salt buffer, a pH stabilizer, and a chelating agent.
In some embodiments, the readout probes are added so they achieve a final concentration of about 10 nM to about 20 μM, or about 10 nM to about 10 μM, or about 100 nM to about 1 μM, about 200 nM to about 500 nM, or about 200 nM, about 300 nM, about 400 nM, or about 500 nM for each readout probe. In some embodiments, the readout probes are added so they achieve a final concentration of about 400 nM.
In some embodiments, the wash buffer can include a salt buffer. In some embodiments, the salt buffer is saline sodium citrate (SSC), NaCl, or MgCl2. In some embodiments, the wash buffer can include about 2× to about 20×, about 5× to about 10×, or about 5× of a salt buffer (e.g., saline sodium citrate (SSC)). In some embodiments, the wash buffer can include about 50 mM to about 500 mM, or about 100 mM to about 300 mM, or about 150 mM to about 250 mM, or about 215 mM or salt buffer (e.g., NaCl).
In some embodiments, the wash buffer can include a pH stabilizer. In some embodiments, the pH stabilizer can be at least one of tris-HCl, citric acid, SSC, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sucrose/EDTA/Tris-HCl (SET), potassium phosphate, tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS), NaOH, 3-(N-morpholino)propanesulfonic acid (MOPS), Tricine, Bicine, sodium pyrophosphate, piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), SSPE. In some embodiments, the pH stabilizer can be tris-HCl. In some embodiments, the wash buffer can include about 5 mM to about 30 mM, about 10 mM to about 20 mM, about 10 mM, or about 20 mM of a pH stabilizer (e.g., tris-HCl).
In some embodiments, the wash buffer can include a chelating agent. In some embodiments, the chelating agent is at least one of EDTA, Ethylene glycol tetraacetic acid (EGTA), Salicylic acid, Triethanolamine (TEA), or Dimercaptopropanol. In some embodiments, the chelating agent is EDTA. In some embodiments, the wash buffer can include about 1 mM to about 10 mM, about 2 mM to about 5 mM, or about 5 mM of a chelating agent (e.g., EDTA).
In some embodiments, the wash buffer can include NaCl, tris-HCl, and EDTA. In some embodiments, the wash buffer can include 215 mM NaCl, 20 mM tris-HCl, and 5 mM EDTA.
After acquiring one or more emission spectra from the first emissive readout probe, an exchange probe is added so it removes the first emissive readout probe from the complex so it allows for another emissive readout probe and imaging step to occur. In some embodiments, the addition of the exchange probe and addition of the second emissive readout probe occur in the same step. In some embodiments, the addition of the exchange probe and addition of the second emissive readout probe occur sequentially.
In some embodiments, the exchange probes are added so they achieve a final concentration of about 10 nM to about 20 or about 10 nM to about 10 or about 100 nM to about 1 about 200 nM to about 500 nM, or about 200 nM, about 300 nM, about 400 nM, or about 500 nM for each exchange probe. In some embodiments, the exchange probes are added so they achieve a final concentration of about 400 nM.
In some embodiments, to contact the exchange probe with the first emissive readout probe to produce a second complex, exchange buffer is added to the sample. In some embodiments, the exchange buffer can include a denaturing/deionizing agent, a salt buffer, a detergent, a polyanionic polymer, a blocking agent, acids, or combinations thereof. In some embodiments, the exchange buffer can include more than one type of agent, for example, the encoding buffer can include two or more polyanionic polymers and/or two or more blocking agents. In some embodiments, the exchange buffer can include a denaturing/deionizing agent, a salt buffer, a detergent, two polyanionic polymers, two blocking agents, and an acid.
In some embodiments, the exchange buffer can include a denaturing/deionizing agent. In some embodiments, the denaturing/deionizing agent can be formamide, ethylene carbonate, or urea. In some embodiments, the exchange buffer can include about 10% (v/v) to about 50% (v/v), about 15% (v/v) to about 45% (v/v), about 20% (v/v) to about 40% (v/v), about 25% (v/v) to about 35% (v/v), about 10% (v/v), 15% (v/v), 20% (v/v), 25% (v/v), or 30% (v/v) of a denaturing/deionizing agent (e.g., ethylene carbonate).
In some embodiments, the exchange buffer can include a salt buffer. In some embodiments, the salt buffer is saline sodium citrate (SSC), NaCl, or MgCl2. In some embodiments, the exchange buffer can include about 2× to about 20×, about 5× to about 10×, or about 5× of a salt buffer (e.g., saline sodium citrate (SSC)).
In some embodiments, the exchange buffer can include at least one polyanionic polymer. In some embodiments, the exchange buffer can include one polyanionic polymer. In some embodiments, the exchange buffer can include two polyanionic polymers. In some embodiments, the polyanionic polymer can be dextran sulfate, heparin, or polyglutamic acid. In some embodiments, the exchange buffer can include about 2.5% (v/v) to about 25% (v/v), about 5% (v/v) to about 15% (v/v), about 7.5% (v/v) to about 12.5% (v/v), about 5% (v/v), or about 10% (v/v) of a polyanionic polymer (e.g., dextran sulfate). In some embodiments, the exchange buffer can include about 20 μg/mL to about 80 μg/mL, about 30 μg/mL to about 70 μg/mL, about 40 μg/mL to about 60 μg/mL, or about 50 μg/mL of a polyanionic polymer (e.g., heparin).
In some embodiments, the exchange buffer can include a detergent. In some embodiments, the detergent can be Tween 20, Tween 80, sodium dodecyl sulfate (SDS), Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58. N-Dodecyl-beta-maltoside, Octyl-beta-glucoside, octylthioglucoside (OTG). In some embodiments, the exchange buffer can include about 0.01% (v/v) to about 1.0% (v/v), about 0.05% (v/v) to about 0.5% (v/v), or about 0.1% (v/v), or about 0.05% (v/v) of detergent (e.g., SDS).
In some embodiments, the exchange buffer can include an acid. In these embodiments, the acid lowers the pH of the buffer. In some embodiments, the acid can be citric acid. In some embodiments, the exchange buffer can include about 1 mM to about 30 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 7 mM to about 10 mM, or about 9 mM of an acid (e.g., citric acid).
In some embodiments, the exchange buffer can include at least one blocking agent. In some embodiments, the exchange buffer can include one blocking agent. In some embodiments, the blocking agents can be Denhardt's solution, bovine serum albumin (BSA), salmon sperm DNA, Ficoll, polyvinyl pyrrolidone (PVP), E. coli tRNA, casein solution, or random hexamers. In some embodiments, the exchange buffer can include about 0.1× to about 10×, about 0.5× to about 5×, about 1× to about 2×, or about 1× of a blocking agent (e.g., Denhardt's solution).
In some embodiments, the exchange buffer can include ethylene carbonate, dextran sulfate, SSC, Denhardt's solution, and SDS. In some embodiments, the exchange buffer can include 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, and 0.01% SDS.
Following the hybridization of the exchange probe to the first emissive readout probe, a second emissive readout probe is added. In some embodiments, this step may be referred to as the “second readout probe hybridization” step. In here, the second emissive readout probe hybridizes to its complementary sequences present in the first complex (e.g., second landing pad sequence).
In some embodiments, the second emissive readout probe hybridization is performed in the presence of the encoding buffer described above. In some embodiments, to image the second readout probes, a wash buffer is added to the sample. In some embodiments, the wash buffer is the wash buffer described above.
In some embodiments, the second emissive readout probes are added so they achieve a final concentration of about 10 nM to about 10 or about 100 nM to about 1 about 200 nM to about 500 nM, or about 200 nM, about 300 nM, about 400 nM, or about 500 nM for each readout probe. In some embodiments, the second emissive readout probes are added so they achieve a final concentration of about 400 nM.
In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, and removing the second complex from the sample are performed in the same step. In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, and removing the second complex from the sample are performed sequentially. In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, removing the second complex from the sample, and adding the second emissive readout probe are performed in the same step. In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, removing the second complex from the sample, and adding the second emissive readout probe are performed sequentially.
In some embodiments, hybridizing the exchange probe to the first or second emissive readout probe results in de-hybridization of the first or second emissive readout probe from the first or second landing pad sequence. In some embodiments, the step is achieved from about 30 seconds to about 1 hour. In some embodiments, the step is achieved within 30 seconds, 1 minute, 5 minutes, 10 minutes, 12 minutes, 15 minutes, 30 minutes, 45 minutes, or 1 hour. In some embodiments, the step is achieved within 1 hour. In some embodiments, the step is achieved overnight.
In another aspect, a method for analyzing a sample can include:
Sample
In some embodiments, the sample is at least one of a cell, a cell suspension, a tissue biopsy, a tissue specimen, urine, stool, blood, serum, plasma, bone biopsies, bone marrow, respiratory specimens, sputum, induced sputum, tracheal aspirates, bronchoalveolar lavage fluid, sweat, saliva, tears, ocular fluid, cerebral spinal fluid, pericardial fluid, pleural fluid, peritoneal fluid, placenta, amnion, pus, nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, ocular swabs, skin swabs, wound swabs, mucosal swabs, buccal swabs, vaginal swabs, vulvar swabs, nails, nail scrapings, hair follicles, corneal scrapings, gavage fluids, gargle fluids, abscess fluids, wastewater, or plant biopsies.
In some embodiments, the sample is a cell. In some embodiments, the cell is a bacterial cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments the eukaryotic cell is a unicellular organism including protozoa, chromista, algae, or fungi. In some embodiments the eukaryotic cell is part of a multicellular organism from chromista, plantae, fungi, or animalia. In some embodiments the sample is a tissue composed of cells. In some embodiments the cell contains foreign DNA/RNA from viruses, plasmids, and bacteria.
In some embodiments, the sample can include a plurality of cells. In some embodiments, each cell in the plurality of cells can include a specific targeting sequence, which may or may not be the same from the other targeting sequences.
In some embodiments, the sample is a human oral microbiome sample. In some embodiments, the sample is a whole organism.
In some embodiments, the sample is obtained from a patient diagnosed with, or suspected to be suffering from an infection, disease, or disorder. In some embodiments, the patient has been diagnosed with, or is suspected to be suffering from a bacterial, viral, fungal, or parasitic infection. In some embodiments, the infection includes, but is not limited to, Acute Flaccid Myelitis, Anaplasmosis, Anthrax, Babesiosis, Botulism, Brucellosis, Campylobacteriosis, Carbapenem-resistant Infection (CRE/CRPA), Chancroid, Chickenpox, Chikungunya Virus Infection (Chikungunya), Chlamydia, Ciguatera (Harmful Algae Blooms (HABs)), Clostridium Difficile Infection, Clostridium Perfringens (Epsilon Toxin), Coccidioidomycosis fungal infection (Valley fever), COVID-19 (Coronavirus Disease 2019), Creutzfeldt-Jacob Disease, transmissible spongiform encephalopathy (CJD), Cryptosporidiosis (Crypto), Cyclosporiasis, Dengue, 1, 2, 3, 4 (Dengue Fever), Diphtheria, E. coli infection, Shiga toxin-producing (STEC), Eastern Equine Encephalitis (EEE), Ebola Hemorrhagic Fever (Ebola), Ehrlichiosis, Encephalitis, Arboviral or parainfectious, Enterovirus Infection, D68 (EV-D68), Enterovirus Infection, Non-Polio (Non-Polio Enterovirus), Giardiasis (Giardia), Glanders, Gonococcal Infection (Gonorrhea), Granuloma inguinale, Haemophilus Influenza disease, Type B (Hib or H-flu), Hantavirus Pulmonary Syndrome (HPS), Hemolytic Uremic Syndrome (HUS), Hepatitis (A, B, C, D, and/or E), Herpes Herpes Zoster, zoster VZV (Shingles), Histoplasmosis infection (Histoplasmosis), Human Immunodeficiency Virus/AIDS (HIV/AIDS), Human Papillomavirus (HPV), Influenza (Flu), Lead Poisoning, Legionellosis (Legionnaires Disease), Leishmaniasis, Leprosy (Hansens Disease), Leptospirosis, Listeriosis (Listeria), Lyme Disease, Lymphogranuloma venereum infection (LGV), Malaria, Measles, Melioidosis, Meningitis, Viral (Meningitis, viral), Meningococcal Disease, Bacterial (Meningitis, bacterial), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Mononucleosis, Multisystem Inflammatory Syndrome in Children (MIS-C), Mumps, Norovirus, Paralytic Shellfish Poisoning (Paralytic Shellfish Poisoning, Ciguatera), Pediculosis (Lice, Head and Body Lice), Pelvic Inflammatory Disease (PID), Pertussis (Whooping Cough), Plague; Bubonic, Septicemic, Pneumonic (Plague), Pneumococcal Disease (Pneumonia), Poliomyelitis (Polio), Powassan, Psittacosis (Parrot Fever), Phthiriasis (Crabs; Pubic Lice Infestation), Pustular Rash diseases (Small pox, monkeypox, cowpox), Q-Fever, Rabies, Ricin Poisoning, Rickettsiosis (Rocky Mountain Spotted Fever), Rubella, Salmonellosis gastroenteritis (Salmonella), Scabies Infestation (Scabies), Scombroid, Septic Shock (Sepsis), Severe Acute Respiratory Syndrome (SARS), Shigellosis gastroenteritis (Shigella), Smallpox, Staphylococcal Infection, Methicillin-resistant (MRSA), Staphylococcal Food Poisoning, Enterotoxin-B Poisoning (Staph Food Poisoning), Staphylococcal Infection, Vancomycin Intermediate (VISA), Staphylococcal Infection, Vancomycin Resistant (VRSA), Streptococcal Disease, Group A (invasive) (Strep A (invasive)), Streptococcal Disease, Group B (Strep-B), Streptococcal Toxic-Shock Syndrome, STSS, Toxic Shock (STSS, TSS), Syphilis, primary, secondary, early latent, late latent, congenital, Tetanus, Toxoplasmosis, Trichomoniasis (Trichomonas infection), Trichinosis Infection (Trichinosis), Tuberculosis (Latent) (LTBI), Tuberculosis (TB), Tularemia (Rabbit fever), Typhus, Typhoid Fever, Group D, Vaginosis, bacterial (Yeast Infection), Vaping-Associated Lung Injury (e-Cigarette Associated Lung Injury), Varicella (Chickenpox), Vibrio cholerae (Cholera), Vibriosis (Vibrio), Viral Hemorrhagic Fever (Ebola, Lassa, Marburg), West Nile Virus, Yellow Fever, Yersenia (Yersinia), or Zika Virus Infection (Zika).
In some embodiments, when the sample is obtained from a patient, the patient has been diagnosed with, or is suspected to be suffering from an infection caused by a bacterium selected from the group consisting of: Acinetobacter, Actinomyces, Aerococcus, Bacteroides, Bartonella, Brucella, Bordetella, Burkholderia, Campylobacter, Chlamydia, Citrobacter, Clostridium, Corynebacterium, Edwardsiella, Elizabethkingia, Enterobacter, Enterococcus, Escherichia, Fusobacterium, Haemophilus, Helicobacter, Klebsiella, Legionella, Leptospira, Listeria, Morganella, Mycobacterium, Mycoplasma, Neisseria, Pantoea, Prevotella, Proteus, Providencia, Pseudomonas, Raoultella, Salmonella, Serratia, Shigella, Staphylococcus, Stenotrophomonas, Streptococcus, Ureaplasma, and Vibrio.
In some embodiments, when the sample is obtained from a patient, the patient has been diagnosed with, or is suspected to be suffering from an infection caused by a virus selected from the group consisting of: bacteriophage, RNA bacteriophage (e.g., MS2, AP205, PP7 and Qβ), Infectious Haematopoietic Necrosis Virus, Parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Measles virus, Mumps virus, Rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, and Poliovirus, Norovirus, Zika virus, Dengue Virus, Rabies Virus, Newcastle Disease Virus, and White Spot Syndrome Virus.
In some embodiments, when the sample is obtained from a patient, the patient has been diagnosed with, or is suspected to be suffering from an infection caused by a parasite selected from the group consisting of: Plasmodium, Trypanosoma, Toxoplasma, Giardia, Leishmania, Cryptosporidium, helminthic parasites: Trichuris spp., Enterobius spp., Ascaris spp., Ancylostoma spp. and Necator spp., Strongyloides spp., Dracunculus spp., Onchocerca spp. and Wuchereria spp., Taenia spp., Echinococcus spp., and Diphyllobothrium spp., Fasciola spp., and Schistosoma spp.
Encoding Probes
Encoding probes are probes that bind directly to a target or targeting sequence and contain either 1 or 2 branches extending away from the hybridization site. The branches can either correspond to the readout sequences or first or second landing pad sequences. Encoding probes, for example, are designed to target bacterial ribosomal RNA (rRNA) and messenger RNA (mRNA) targets.
For example, rRNA-probes can contain (5′ to 3′):
a. Primer sequences to enrich probe pool.
b. A first landing pad sequence.
c. rRNA target complementary sequence.
d. A second landing pad sequence (different than b).
e. Primer sequences to enrich probe pool.
mRNA-probes contain (5′ to 3′):
a. Primer sequences to enrich probe pool.
b. A first landing pad sequence.
c. mRNA target complementary sequence.
d. A second landing pad sequence (different than b).
e. Primer sequences to enrich probe pool.
In some embodiments, each encoding probe can include a targeting sequence, a first landing pad sequence and a second landing pad sequence.
Primer Sequences
In some embodiments, the primer sequence can include about 10 to about 30, about 15 to about 25, about 18 to about 23, about 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides long.
Targeting Sequence
In some embodiments, the targeting sequence targets at least one of messenger RNA (mRNA), micro RNA (miRNA), long non coding RNA (lncRNA), ribosomal RNA (rRNA), small interfering RNA (siRNA), transfer RNA (tRNA), Crispr RNA (crRNA), trans-activating cirspr RNA (tracrRNA), mitochondria RNA, Intronic RNA, viral mRNA, viral genomic RNA, environmental RNA, double-stranded RNA (dsRNA), small nuclear RNA (snRNA), small nucleolar (snoRNA), piwi-interacting RNA (piRNA), genomic DNA, synthetic DNA, DNA, plasmid DNA, a plasmid, viral DNA, retroviral DNA, environmental DNA, extracellular DNA, a protein, a small molecule, or an antigenic target. In some embodiments, the target is mRNA. In some embodiments, the target is rRNA. In some embodiments, the target is mRNA and rRNA.
In some embodiments, the targeting sequence of the encoding probe is substantially complementary to a specific target sequence. By “substantially complementary” it is meant that the nucleic acid fragment is capable of hybridizing to at least one nucleic acid strand or duplex even if less than all nucleobases do not base pair with a counterpart nucleobase. In some embodiments, a “substantially complementary” nucleic add contains at least one sequence in which about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 77%, 8%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, to about 100%, and any range therein, of the nucleobase sequence is capable of basepairing with at least one single or double stranded nucleic acid molecule during hybridization.
In some embodiments, the targeting sequence is designed to have a predicted melting temperature of between about 55° C. and about 65° C. In some embodiments, the predicted melting temperature of the targeting sequence is 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C. or 65° C. In some embodiments, the targeting sequence can have a GC content of about 55%, 60%, 65% or 70%.
In some embodiments, the targeting sequence can include about 10 to about 35, about 15 to about 30, about 18 to about 30, about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides long.
In some embodiments, the targeting sequence of an encoding probe is designed using publicly-available sequence data. In some embodiments, the targeting sequence of an encoding probe design is designed using custom catalogues of the target/sample. In some embodiments, the targeting sequence of an encoding probe is designed using a database that is relevant for a system. In a specific embodiment, the system is the gut microbiome. In some embodiments, the targeting sequence of an encoding probe is designed using a database that is relevant for a disease or infection.
Landing Pad Sequences
In some embodiments, the encoding probe can include a first landing pad sequence on the 5′ end and a second landing pad sequence on the 3′ end. In some embodiments, the first and second landing pad sequences have the same sequence.
In some embodiments, each landing pad sequence is about 10 to about 50, about 15 to about 50, about 15 to about 40, about 10 to about 30, about 15 to about 25, about 18 to about 23, about 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides long. In some embodiments, each landing pad sequence is substantially complementary to the first and/or second emissive readout sequences.
The encoding probes, and other probes described herein, may be introduced into the sample (e.g., cell) using any suitable method. In some cases, the sample may be sufficiently permeabilized such that the probes may be introduced into the sample by flowing a fluid containing the probes around the sample (e.g., cells). In some cases, the samples (e.g., cells) may be sufficiently permeabilized as part of a fixation process. In some embodiments, samples (e.g., cells) may be permeabilized by exposure to certain chemicals such as ethanol, methanol, Triton, or the like. In some embodiments, techniques such as electroporation or microinjection may be used to introduce the probes into a sample (e.g., cell).
Emissive Readout Probes
Emissive readouts probes are oligonucleotides bound with one of ten fluorescent dyes at the 5′- and/or 3′-end. In some embodiments, each emissive readout probe comprises a label and a sequence complementary to the first landing pad sequence.
In some embodiments, each emissive readout probe sequence is of the same length as the first or second landing pad sequence. In some embodiments, the emissive readout probe sequence is 0 nucleotides longer than the corresponding landing pad sequence.
In some embodiments, each emissive readout probe sequence is from at least 1 to at least 35 nucleotides longer than the corresponding landing pad sequence. In some embodiments, each emissive readout probe sequence is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or 35 nucleotides longer than the corresponding landing pad sequence. In some embodiments, each emissive readout probe sequence is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides longer than the corresponding landing pad sequence. In some embodiments, each emissive readout probe sequence is at least 5 nucleotides longer than the corresponding landing pad sequence.
Readout probes can be designed as follows:
a. Are coupled to 1, 2, or more fluorescent dyes.
b. Are orthogonal to all biological sequences.
c. Are orthogonal to each other/each other's complementary sequences.
In some embodiments, the readout sequence is about 10 to about 50, about 15 to about 50, about 15 to about 45, about 15 to about 35, about 15 to about 30, about 18 to about 24, about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 nucleotides long.
In some embodiments, the emissive readout probe can include a label on the 5′ or 3′ end. In some embodiments, the emissive readout probe can include a label on the 5′ end and a label on the 3′ end. In some embodiments, the labels are the same. In some embodiments, the labels are different.
In some embodiments, the label is a fluorescent entity (fluorophore) or phosphorescent entity. In some embodiments, the label is a cyanine dye (e.g., Cy2, Cy3, Cy3B, Cy5, Cy5.5, Cy7, etc.), Alexa Fluor dye, Atto dye, photo switchable dye, photoactivatable dye, fluorescent dye, metal nanoparticle, semiconductor nanoparticle or “quantum dots”, fluorescent protein such as GFP (Green Fluorescent Protein), or photoactivatable fluorescent protein, such as PAGFP, PSCFP, PSCFP2, Dendra, Dendra2, EosFP, tdEos, mEos2, mEos3, PAmCherry, PAtagRFP, mMaple, mMaple2, and mMaple3.
In some embodiments, the label is Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 561, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor 647-R-phycoerythrin, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 680-allophycocyanin, Alexa Fluor 700, Alexa Fluor 750, Alexa Fluor 790, Alexa Fluor Plus 405, Alexa Fluor Plus 488, Alexa Fluor Plus 555, Alexa Fluor Plus 594, Alexa Fluor Plus 647, Alexa Fluor Plus 680, Alexa Fluor Plus 750, Alexa Fluor Plus 800, Pacific Blue, Pacific Green, Rhodamine Red X, DyLight 485-LS, DyLight-510-LS, DyLight 515-LS, DyLight 521-LS, Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Fluorescein FITC, R-phycoerythrin (PE), Tamara, Cy3.5 581, ROX (carboxy-X-rhodamine), Red 613, Texas Red, Cy5, Cy5.5, Cy7, Allophycocyanin, ATTO 430LS, ATTO 490LS, ATTO 390, ATTO 425, Cyan 500 NHS-Ester, ATTO 465, ATTO 488, ATTO 495, ATTO Rho110, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 643, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740.
In some embodiments, the label is imaged using widefield microscopy, point scanning confocal microscopy, spinning disk confocal microscopy, lattice lightsheet microscopy, or light field microscopy.
In some embodiments, the detection strategy used is channel, spectral, channel and fluorescence lifetime, or spectral and fluorescence lifetime.
In some embodiments, the labels used in the present methods are imaged using a microscope. In some embodiments, the microscope is a confocal microscope. In some embodiments, the microscope is a fluorescence microscope. In some embodiments, the microscope is a light-sheet microscope. In some embodiments, the microscope is a super-resolution microscope.
In some embodiments, the sample is on an analyzing platform, wherein the analyzing platform is a microscope slide, at least one chamber, at least one microfluidic device, at least one well, at least one plate, or at least one filter membrane.
Exchange Probes
Exchange probes are each about 10-50 or 15-50 nucleotide-long oligonucleotides. In some embodiments, each exchange probe comprises a 100% complementary sequence to a respective emissive readout probe sequence.
In some embodiments, the exchange sequence is about 10 to about 50, about 15 to about 50, about 15 to about 45, about 15 to about 35, about 15 to about 30, about 18 to about 24, about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 nucleotides long.
In some embodiments, the encoding probes contain locked nucleic acids to stabilize the exchange reaction.
In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, and removing the second complex from the sample are performed in the same step. In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, and removing the second complex from the sample are performed sequentially. In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, removing the second complex from the sample, and adding the second emissive readout probe are performed in the same step. In some embodiments, adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, removing the second complex from the sample, and adding the second emissive readout probe are performed sequentially.
In some embodiments, hybridizing the exchange probe to the first or second emissive readout probe results in de-hybridization of the first or second emissive readout probe from the first or second landing pad sequence. In some embodiments, the step is achieved from about 30 seconds to about 1 hour. In some embodiments, the step is achieved within 30 seconds, 1 minute, 5 minutes, 10 minutes, 12 minutes, 15 minutes, 30 minutes, 45 minutes, or 1 hour. In some embodiments, the step is achieved within 1 hour. In some embodiments, the step is achieved overnight.
In another aspect, a method for analyzing a bacterial sample can include:
In another aspect, a method for analyzing a bacterial sample, comprising:
Constructs and Libraries
In another aspect, a construct can include:
In another aspect, a library of constructs comprising a plurality of barcoded probes, wherein each barcoded probe can include:
In some embodiments, the region of interest on a nucleotide is at least one of messenger RNA (mRNA), microRNA (miRNA), long non coding RNA (lncRNA), ribosomal RNA (rRNA), small interfering RNA (siRNA), transfer RNA (tRNA), Crispr RNA (crRNA), trans-activating CRISPR RNA (tracrRNA), mitochondrial RNA, intronic RNA, viral mRNA, viral genomic RNA, environmental RNA, double-stranded RNA (dsRNA), small nuclear RNA (snRNA), small nucleolar (snoRNA), PIWI-interacting RNA (piRNA), genomic DNA, synthetic DNA, DNA, plasmid DNA, a plasmid, viral DNA, retroviral DNA, environmental DNA, extracellular DNA, a protein, a small molecule, or an antigen.
In some embodiments, the region of interest on a nucleotide is mRNA.
In some embodiments, the region of interest on a nucleotide is rRNA.
In some embodiments, the region of interest on a nucleotide is mRNA and rRNA.
In some embodiments, the first and second landing pad sequences have the same sequence. In some embodiments, the first and second landing pad sequences have different sequences.
In some embodiments, the first and second landing pad sequences each are about 10 to about 50, about 10 to about 40, about 10 to about 30, about 15 to about 25, about 18 to about 23, about 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides long. In some embodiments, the first and second landing pad sequences each are substantially complementary to the first and/or second emissive readout sequences.
In some embodiments, the first and second emissive readout probes are each about 10 to about 50, about 10 to about 40, about 10 to about 30, about 15 to about 25, about 18 to about 23, about 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides long bound with one of ten fluorescent dyes at the 5′- and/or 3′-end. In some embodiments, the first and second emissive readout probes each comprise a label and a sequence complementary to the first or second landing pad sequence.
In some embodiments, the first and second emissive readout probes are each of the same length as the corresponding landing pad sequence. In some embodiments, the first and second emissive readout probes are each 0 nucleotides longer than the corresponding landing pad sequence. In some embodiments, the first and second emissive readout probes are each at least 2 to 50 nucleotides longer than the corresponding landing pad sequence. In some embodiments, the first and second emissive readout probes are each at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides longer than the corresponding landing pad sequence. In some embodiments, the first and second emissive readout probes are each at least 1, 2, 3, 4, or 5 nucleotides longer than the corresponding landing pad sequence. In some embodiments, the first and second emissive readout probes are each at least 5 nucleotides longer than the corresponding landing pad sequence.
In some embodiments, the readout sequence of the first and second emissive readout probes are each about 15 to about 50, about 15 to about 45, about 15 to about 35, about 15 to about 30, about 18 to about 24, about 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 nucleotides long.
In some embodiments, the emissive readout probe can include a label on the 5′ or 3′ end. In some embodiments, the emissive readout probe can include a label on the 5′ end and a label on the 3′ end. In some embodiments, the emissive readout probe can contain internal labels which may be the same or different. In some embodiments, the labels are the same. In some embodiments, the labels are different.
In some embodiments, the label is a fluorescent entity (fluorophore) or phosphorescent entity. In some embodiments, the label is a cyanine dye (e.g., Cy2, Cy3, Cy3B, Cy5, Cy5.5, Cy7, etc.), Alexa Fluor dye, Atto dye, photo switchable dye, photoactivatable dye, fluorescent dye, metal nanoparticle, semiconductor nanoparticle or “quantum dots”, fluorescent protein such as GFP (Green Fluorescent Protein), or photoactivatable fluorescent protein, such as PAGFP, PSCFP, PSCFP2, Dendra, Dendra2, EosFP, tdEos, mEos2, mEos3, PAmCherry, PAtagRFP, mMaple, mMaple2, and mMaple3.
In some embodiments, the label is Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 561, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor 647-R-phycoerythrin, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 680-allophycocyanin, Alexa Fluor 700, Alexa Fluor 750, Alexa Fluor 790, Alexa Fluor Plus 405, Alexa Fluor Plus 488, Alexa Fluor Plus 555, Alexa Fluor Plus 594, Alexa Fluor Plus 647, Alexa Fluor Plus 680, Alexa Fluor Plus 750, Alexa Fluor Plus 800, Pacific Blue, Pacific Green, Rhodamine Red X, DyLight 485-LS, DyLight-510-LS, DyLight 515-LS, DyLight 521-LS, Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Fluorescein FITC, R-phycoerythrin (PE), Tamara, Cy3.5 581, Rox, Red 613, Texas Red, Cy5, Cy5.5, Cy7, Allophycocyanin, ATTO 430LS, ATTO 490LS, ATTO 390, ATTO 425, Cyan 500 NHS-Ester, ATTO 465, ATTO 488, ATTO 495, ATTO Rho110, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 643, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740.
Embodiments of the present subject matter disclosed herein may be beneficial alone or in combination with one or more other embodiments. Without limiting the foregoing description, certain non-limiting embodiments of the disclosure, numbered I-1 to 11-37 are provided below. As will be apparent to those of skill in the art upon reading this disclosure, each of the individually numbered embodiments may be used or combined with any of the preceding or following individually numbered embodiments. This is intended to provide support for all such combinations of embodiments and is not limited to combinations of embodiments explicitly provided below.
Embodiment I-1: A method of characterizing a microbial cell from a biological sample, the method comprising a) directly inoculating the microbe onto a device; b) identifying the microbe; and c) detecting susceptibility to one or more antimicrobial agents.
Embodiment II-1: A method of characterizing a microbial cell from a biological sample, the method comprising a) directly inoculating the microbe onto a device; b) identifying the microbe; and c) detecting future susceptibility to one or more antimicrobial agents.
Embodiment II-2: The method of embodiments I-1 or II-1, wherein the sample is not subjected to culturing before the microbe is inoculated onto the device.
Embodiment II-3: The method of embodiments I-1 or II-1 to II-2, wherein the microbe in the sample is cultured for one to 12 cell divisions before it is inoculated onto the device.
Embodiment II-4: The method of embodiments I-1 or II-1 to II-3, wherein the microbe is identified by in situ hybridization.
Embodiment II-5: The method of embodiments I-1 or II-1 to II-4, wherein the microbe is identified by fluorescence in situ hybridization (FISH).
Embodiment II-6: The method of embodiments I-1 or II-1 to II-5, wherein the fluorescence in situ hybridization is high-phylogenetic-resolution fluorescence in situ hybridization (HiPR-FISH).
Embodiment II-7: The method of embodiments I-1 or II-1 to II-6, wherein the microbe is further characterized via live-cell imaging or dynamic calculation while in situ hybridization is performed.
Embodiment II-8: The method of embodiments I-1 or II-1 to II-7, wherein the microbe is identified by hybridization of a bar-coded probe a 16S ribosomal RNA sequence in the microbe, 5S ribosomal RNA sequence in the microbe, and/or 23S ribosomal RNA sequence in the microbe.
Embodiment II-9: The method of embodiments I-1 or II-1 to II-8, wherein the in situ hybridization is multiplexed.
Embodiment II-10: The method of embodiments I-1 or II-1 to II-9, wherein the susceptibility to one or more microbial agents is determined by measuring the minimum inhibitory concentration of the microbe when exposed to an antimicrobial agent.
Embodiment II-11: The method of embodiments I-1 or II-1 to II-10, wherein the susceptibility to one or more microbial agents is determined by measuring microbial cell metabolism when the microbe is exposed to an antimicrobial agent.
Embodiment II-12: The method of embodiments I-1 or II-1 to II-11, wherein microbial cell metabolism is measured by determining the concentration of dissolved carbon dioxide, oxygen consumption of microbes in the sample, expression of genes involved in cell division and/or growth, or expression of stress response genes.
Embodiment II-13: The method of embodiments I-1 or II-1 to II-12, wherein microbial cell susceptibility is determined by a live/dead stain.
Embodiment II-14: The method of embodiments I-1 or II-1 to II-13, wherein microbial cell susceptibility is determined by cell number.
Embodiment II-15: The method of embodiments I-1 or II-1 to II-14, wherein microbial cell susceptibility is determined by detecting the presence or absence of one or more antimicrobial genes in the microbial cell.
Embodiment II-16: The method of embodiments I-1 or II-1 to II-15, wherein microbial cell susceptibility is determined by detecting the presence or absence of one or more gene mutations associated with the development of antimicrobial resistance or susceptibility in the microbial cell.
Embodiment II-17: The method of embodiments I-1 or II-1 to II-16, wherein future microbial cell susceptibility is determined by detecting the presence or absence of one or more antimicrobial genes in the microbial cell.
Embodiment II-18: The method of embodiments I-1 or II-1 to II-17, wherein future microbial cell susceptibility is determined by detecting the presence or absence of one or more gene mutations associated with the development of antimicrobial resistance or susceptibility in the microbial cell.
Embodiment II-19: The method of embodiments I-1 or II-1 to II-18, wherein the one or more gene mutations associated with the development of antimicrobial resistance or susceptibility is selected from deletions, duplications, single nucleotide polymorphisms (SNPs), frame-shift mutations, inversions, insertions, and/or nucleotide substitutions.
Embodiment II-20: The method of embodiments I-1 or II-1 to II-19, wherein the one or more antimicrobial genes is selected from: genes encoding multidrug resistance proteins (e.g. PDR1, PDR3, PDR7, PDR9), ABC transporters (e.g. SNQ2, STE6, PDR5, PDR10, PDR11, YOR1), membrane associated transporters (GAS1, D4405), soluble proteins (e.g. G3PD), RNA polymerase, rpoB, gyrA, gyrB, 16S RNA, 23S rRNA, NADPH nitroreductase, sul2, strAB, tetAR, aac3-iid, aph, sph, cmy-2, floR, tetB; aadA, aac3-VIa, and sul1.
Embodiment II-21: The method of embodiments I-1 or II-1 to II-20, wherein the presence or absence of one or more antimicrobial genes, or the gene mutation associated with the development of antimicrobial resistance or susceptibility in the microbial cell is detected using in situ hybridization.
Embodiment II-22: The method of embodiments I-1 or II-1 to II-21, wherein the presence or absence of one or more antimicrobial genes, or the gene mutation associated with the development of antimicrobial resistance or susceptibility in the microbial cell is detected using fluorescence in situ hybridization (FISH).
Embodiment II-23: The method of embodiments I-1 or II-1 to II-22, wherein the fluorescence in situ hybridization is high-phylogenetic-resolution fluorescence in situ hybridization (HiPR-FISH).
Embodiment II-24: The method of embodiments I-1 or II-1 to II-23, wherein the identification of the microbial cell and the detection of susceptibility or future susceptibility to one or more antimicrobial agents occurs sequentially.
Embodiment II-25: The method of embodiments I-1 or II-1 to II-24, wherein the identification of the microbial cell and the detection of susceptibility or future susceptibility to one or more antimicrobial agents occurs simultaneously.
Embodiment II-26: The method of embodiments I-1 or II-1 to II-25, wherein the identification of the microbial cell and the detection of susceptibility or future susceptibility to one or more antimicrobial agents occurs in parallel.
Embodiment II-27: The method of embodiments I-1 or II-1 to II-26, wherein the biological sample is obtained from a patient.
Embodiment II-28: The method of embodiments I-1 or II-1 to II-27, wherein the biological sample is obtained from a patient diagnosed with or believed to be suffering from an infection or disorder.
Embodiment II-29: The method of embodiments I-1 or II-1 to II-28, wherein the disease or disorder is an infection.
Embodiment II-30: The method of embodiments I-1 or II-1 to II-29, wherein the infection is a bacterial, viral, fungal, or parasitic infections.
Embodiment II-31: The method of embodiments I-1 or II-1 to II-30, wherein the bacterial infection is selected from Mycobacterium, Streptococcus, Staphylococcus, Shigella, Campylobacter, Salmonella, Clostridium, Corynebacterium, Pseudomonas, Neisseria, Listeria, Vibrio, Bordetella, E. coli (including pathogenic E. coli), Pseudomonas aeruginosa, Enterobacter cloacae, Mycobacterium tuberculosis, Staphylococcus aureus, Helicobacter pylori, Legionella, Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus saprophyticus, and Streptococcus agalactiae, or a combination thereof.
Embodiment II-32: The method of embodiments I-1 or II-1 to II-30, wherein the viral infection is selected from Helicobacter pylori, infectious haematopoietic necrosis virus (IHNV), Parvovirus B19, Herpes Simplex Virus, Varicella-zoster virus, Cytomegalovirus, Epstein-Barr virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Measles virus, Mumps virus, Rubella virus, Human Immunodeficiency Virus (HIV), Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, Norovirus, Zika Virus, Dengue Virus, Rabies Virus, Newcastle Disease Virus, and White Spot Syndrome Virus, or a combination thereof.
Embodiment II-33: The method of embodiments I-1 or II-1 to II-30, wherein the fungal infection is selected from Aspergillus, Candida, Pneumocystis, Blastomyces, Coccidioides, Cryptococcus, and Histoplasma, or a combination thereof.
Embodiment II-34: The method of embodiments I-1 or II-1 to II-30, wherein the parasitic infection is selected from Plasmodium (i.e. P. falciparum, P. malariae, P. ovale, P. knowlesi, and P. vivax), Trypanosoma, Toxoplasma, Giardia, and Leishmania, Cryptosporidium, helminthic parasites: Trichuris spp. (whipworms), Enterobius spp. (pinworms), Ascaris spp. (roundworms), Ancylostoma spp. and Necator spp. (hookworms), Strongyloides spp. (threadworms), Dracunculus spp. (Guinea worms), Onchocerca spp. and Wuchereria spp. (filarial worms), Taenia spp., Echinococcus spp., and Diphyllobothrium spp. (human and animal cestodes), Fasciola spp. (liver flukes) and Schistosoma spp. (blood flukes), or a combination thereof.
Embodiment II-35: The method of embodiments I-1 or II-1 to II-34, wherein the biological sample is selected from bronchoalveolar lavage fluid (BAL), blood, serum, plasma, urine, cerebrospinal fluid, pleural fluid, synovial fluid, ocular fluid, peritoneal fluid, amniotic fluid, gastric fluid, lymph fluid, interstitial fluid, tissue homogenate, cell extracts, saliva, sputum, stool, physiological secretions, tears, mucus, sweat, milk, semen, seminal fluid, vaginal secretions, fluid from ulcers and other surface eruptions, blisters, and abscesses, and extracts of tissues including biopsies of normal, malignant, and suspect tissues or any other constituents of the body which may contain the microorganism of interest.
Embodiment II-36: The method of embodiments I-1 or II-1 to II-34, wherein the biological sample is a human oral microbiome sample.
Embodiment II-37: The method of embodiments I-1 or II-1 to II-34, wherein the biological sample is a whole organism.
Embodiment III-1: A method for analyzing a sample, comprising:
Embodiment IV-1: A method for analyzing a sample, comprising:
Embodiment IV-2: The method of embodiments III-1 or IV-1, wherein the sample is at least one of a cell, a cell suspension, a tissue biopsy, a tissue specimen, urine, stool, blood, serum, plasma, bone biopsies, bone marrow, respiratory specimens, sputum, induced sputum, tracheal aspirates, bronchoalveolar lavage fluid, sweat, saliva, tears, ocular fluid, cerebral spinal fluid, pericardial fluid, pleural fluid, peritoneal fluid, placenta, amnion, pus, nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, ocular swabs, skin swabs, wound swabs, mucosal swabs, buccal swabs, vaginal swabs, vulvar swabs, nails, nail scrapings, hair follicles, corneal scrapings, gavage fluids, gargle fluids, abscess fluids, wastewater, or plant biopsies.
Embodiment IV-3: The method of embodiment IV-2, wherein the sample is a cell.
Embodiment IV-4: The method of embodiment IV-3, wherein the cell is a bacterial or eukaryotic cell.
Embodiment IV-5: The method of embodiment IV-2, wherein the sample comprises a plurality of cells.
Embodiment IV-6: The method of embodiment IV-5, wherein each cell comprises a specific targeting sequence.
Embodiment IV-7: The method of Embodiments III-1 or IV-1, wherein the targeting sequence targets at least one of messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA), ribosomal RNA (rRNA), small interfering RNA (siRNA), transfer RNA (tRNA), Crispr RNA (crRNA), trans-activating CRISPR RNA (tracrRNA), mitochondrial RNA, intronic RNA, viral mRNA, viral genomic RNA, environmental RNA, double-stranded RNA (dsRNA), small nuclear RNA (snRNA), small nucleolar (snoRNA), PIWI-interacting RNA (piRNA), genomic DNA, synthetic DNA, DNA, plasmid DNA, a plasmid, viral DNA, retroviral DNA, environmental DNA, extracellular DNA, a protein, a small molecule, or an antigenic target.
Embodiment IV-8: The method of embodiment IV-7, wherein the target is mRNA.
Embodiment IV-9: The method of embodiment IV-7, wherein the target is rRNA.
Embodiment IV-10: The method of embodiment IV-7, wherein the target is mRNA and rRNA.
Embodiment IV-11: The method of Embodiments III-1 or IV-1, wherein the at least one encoding probe comprises the first landing pad sequence on the 5′ end, and the second landing pad sequence on the 3′ end.
Embodiment IV-12: The method of Embodiments III-1 or IV-1, wherein the at least one encoding probe comprises the first landing pad sequence on the 3′ end, and the second landing pad sequence on the 5′ end.
Embodiment IV-13: The method of embodiment IV-12, wherein the first landing pad sequence and the second landing pad sequences have different sequences.
Embodiment IV-14: The method of Embodiments III-1 or IV-1, wherein the at least one first or second emissive readout probe comprises a label on the 5′ or 3′ end.
Embodiment IV-15: The method of Embodiments III-1 or IV-1, wherein the label is Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 561, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor 647-R-phycoerythrin, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 680-allophycocyanin, Alexa Fluor 700, Alexa Fluor 750, Alexa Fluor 790, Alexa Fluor Plus 405, Alexa Fluor Plus 488, Alexa Fluor Plus 555, Alexa Fluor Plus 594, Alexa Fluor Plus 647, Alexa Fluor Plus 680, Alexa Fluor Plus 750, Alexa Fluor Plus 800, Pacific Blue, Pacific Green, Rhodamine Red X, DyLight 485-LS, DyLight-510-LS, DyLight 515-LS, DyLight 521-LS, Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Fluorescein FITC, R-phycoerythrin (PE), Tamara, Cy3.5 581, Rox, Red 613, Texas Red, Cy5, Cy5.5, Cy7, Allophycocyanin, ATTO 430LS, ATTO 490LS, ATTO 390, ATTO 425, Cyan 500 NHS-Ester, ATTO 465, ATTO 488, ATTO 495, ATTO Rho110, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 643, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740.
Embodiment IV-16: The method of Embodiments III-1 or IV-1, wherein the one or more emission spectra of the first and/or second emissive readout probe is acquired via widefield microscopy, point scanning confocal microscopy, spinning disk confocal microscopy, lattice lightsheet microscopy, or light field microscopy.
Embodiment IV-17: The method of embodiment IV-17, wherein the detection strategy used is channel, spectral, channel and fluorescence lifetime, or spectral and fluorescence lifetime.
Embodiment IV-18: The method of Embodiments III-1 or IV-1, wherein the sample is on an analyzing platform, wherein the analyzing platform is a microscope slide, at least one chamber, at least one microfluidic device, at least one well, at least one plate, or at least one filter membrane.
Embodiment IV-19: The method of Embodiments III-1 or IV-1, wherein adding an exchange probe to the sample, hybridizing the exchange probe to the first emissive readout probe, and removing the second complex from the sample are performed in the same step.
Embodiment IV-20: The method of Embodiments III-1 or IV-1, wherein hybridizing the exchange probe to the first or second emissive readout probe results in de-hybridization of the first or second emissive readout probe from the first or second landing pad sequence.
Embodiment IV-21: The method of embodiments IV-19 or IV-20, wherein the step is achieved within 1 hour.
Embodiment IV-22: The method of embodiments IV-19 or IV-20, wherein the step is achieved overnight.
Embodiment IV-23: The method of any one of embodiments III-1, or IV-1 to IV-22, wherein the emissive readout probe sequence is at least 5 nucleotides longer than the first or second landing pad sequences.
Embodiment V-1: A construct comprising:
Embodiment VI-1: A library of constructs comprising a plurality of barcoded probes, wherein each barcoded probe comprises:
Embodiment VI-2: The construct of embodiments V-1 or VI-2, wherein the first emissive readout probe sequence is at least 5 nucleotides longer than the first landing pad sequence.
Embodiment VI-3: The construct of embodiments V-1 or VI-2, wherein the second emissive readout probe sequence is at least 5 nucleotides longer than the second landing pad sequence.
Embodiment VI-4: The construct of embodiments V-1 or VI-2, wherein the first landing pad sequence and the second landing pad sequences have different sequences.
Embodiment VI-5: The construct of embodiments V-1 or VI-2, wherein the first emissive readout probe comprises the first label on the 5′ or 3′ end.
Embodiment VI-6: The construct of embodiments V-1 or VI-2, wherein the second emissive readout probe comprises the second label on the 5′ or 3′ end.
Embodiment VI-7: The construct of embodiments V-1 or VI-2, wherein the first or second label is each Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 561, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor 647-R-phycoerythrin, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 680-allophycocyanin, Alexa Fluor 700, Alexa Fluor 750, Alexa Fluor 790, Alexa Fluor Plus 405, Alexa Fluor Plus 488, Alexa Fluor Plus 555, Alexa Fluor Plus 594, Alexa Fluor Plus 647, Alexa Fluor Plus 680, Alexa Fluor Plus 750, Alexa Fluor Plus 800, Pacific Blue, Pacific Green, Rhodamine Red X, DyLight 485-LS, DyLight-510-LS, DyLight 515-LS, DyLight 521-LS, Hydroxycoumarin, methoxycoumarin, Cy2, FAM, Fluorescein FITC, R-phycoerythrin (PE), Tamara, Cy3.5 581, Rox, Red 613, Texas Red, Cy5, Cy5.5, Cy7, Allophycocyanin, ATTO 430LS, ATTO 490LS, ATTO 390, ATTO 425, Cyan 500 NHS-Ester, ATTO 465, ATTO 488, ATTO 495, ATTO Rho110, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 643, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, or ATTO 740.
Embodiment VII-1: A method for analyzing a bacterial sample, comprising:
Embodiment VIII-1: A method for analyzing a bacterial sample, comprising:
To enable parallel measurement of cellular state at different antibiotic concentrations, microbial cells are colocalized with a volume of antibiotic solution with a known concentration. This objective can potentially be achieved in several ways.
Solution 1: a buffer containing cells are applied to a plate with microfabricated wells (well size can be hundreds of microns to millimeters). Cells may be allowed to settle into individual wells by gravity or by centrifugation. After cell settlement, excess solutions are removed. Subsequently, a hydrated gel (agar, agarose, polyethylene glycol, or polyacrylamide, for example) loaded with an antimicrobial gradient can be applied over the top of the plate, allowing different wells to be exposed to different concentrations of antimicrobial compounds. Solution 2: a buffer containing cells are passed through a microfluidic device to convert the bulk solution into a solution of droplets, where each droplet may contain zero or more cells. The cell droplets are then merged with droplets of antimicrobial solutions using a second microfluidic device, allowing different cells to be exposed to antimicrobial solutions at different concentrations. The antimicrobial solution can be colored with food coloring, or other bacteria-compatible dyes, to allow them to be distinguished on an imaging device. Solution 3: a buffer containing cells are microencapsulated into semipermeable polymeric beads. The polymer beads containing microbial cells are then distributed into wells on a plate, where each well contains a known concentration of antimicrobial compounds.
The methods of the disclosure were used to identify microbes and drug-resistance phenotype in patient urine samples. The experimental set up is shown in
Specimens were stored in a mixture of urine supernatant and glycerol and frozen at −80° C. until time of processing. Specimens were thawed and deposited onto the device and incubated at 37° C. for one hour. The specimen was biologically fixed by depositing 2% formaldehyde onto the specimen and incubated for thirty minutes at room temperature. The specimens were washed using 1×PBS multiple times at room temperature. An encoding buffer (2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) with probes designed for a panel of uropathogens (at roughly 200 nM per taxon) was deposited on cells and incubated for two hours at 37° C. A wash buffer (5 mM EDTA, 20 mM Tris HCl, 215 mM NaCl) was then deposited on specimens for fifteen minutes at 37° C. to remove unbound probes. A buffer containing readout probes (10 readout probes, each at 400 nM; buffer made up of 2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) was incubated for 30 minutes at room temperature. A second round of wash buffer was deposited on specimens for fifteen minutes at 37° C. to remove unbound probe. The specimens were then suspended in 2×SSC and a coverslip was placed directly over the specimens for imaging on a confocal microscope.
Suspensions of individual monocultures were fixed by adding an equal volume of 2% formaldehyde, mixing, and incubating for 90 minutes at room temperature. Fixed cultures were then washed with 1×PBS and resuspended in 50% ethanol. Single taxa suspensions or mixed suspensions containing multiple taxa, were deposited onto glass microscope slides until 50% ethanol had evaporated. Lysosyme (10 mg/mL) was deposited onto each dry specimen to permeabilize the outer membrane and incubated for 30 minutes at 37° C., the slides were then washed with 1×PBS. An encoding probe hybridization buffer (2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) with probes designed for a panel of uropathogens (at roughly 200 nM per taxon) was deposited on cells and incubated for two hours at 37° C. A wash buffer (5 mM EDTA, 20 mM Tris HCl, 215 mM NaCl) was then deposited on specimens for fifteen minutes at 37° C. to remove unbound probes. A buffer containing readout probes (10 readout probes, each at 400 nM; buffer made up of 2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) was incubated for one hour at room temperature. A second round of wash buffer was deposited on specimens for fifteen minutes at 37° C. to remove unbound probe. The specimens were mounted with Prolong Glass and a coverslip was placed directly over the specimens for imaging on confocal microscope.
Table 1 shows the sequences of the readout probes used various Examples disclosed herein. Table 2 shows the sequences of the encoding probes used in Examples 2.1 and 2.2.
Suspensions of individual monocultures were fixed by adding an equal volume of 2% formaldehyde, mixing, and incubating for 90 minutes at room temperature. Fixed cultures were then washed with 1×PBS and resuspended in 50% ethanol. Suspensions were deposited onto glass microscope slides until 50% ethanol had evaporated. Zymolysae (5 U per mL in a buffer with 1.2 M sorbitol and 0.1 M potassium phosphate buffer, pH 7.5) was deposited onto each dry specimen to permeabilize the outer membrane and incubated for 90 minutes at 30° C., the slides were then washed with 1×PBS. An encoding probe hybridization buffer (2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) with probes designed for the fungal species (at roughly 200 nM) was deposited on cells and incubated for two hours at 37° C. A wash buffer (5 mM EDTA, 20 mM Tris HCl, 215 mM NaCl) was then deposited on specimens for fifteen minutes at 37° C. to remove unbound probes. A buffer containing readout probes (10 readout probes, each at 400 nM; buffer made up of 2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) was incubated for one hour at room temperature. A second round of wash buffer was deposited on specimens for fifteen minutes at 37° C. to remove unbound probes. The specimens were mounted with Prolong Glass and a coverslip was placed directly over the specimens for imaging on a confocal microscope.
Table 3 shows the sequences of the encoding probes used in this example. The readout probes are shown in Table 1.
Escherichia coli (E. coli) cells were cultured at 30° C. for several passages prior to the start of the experiment. At experiment passage, cultured E. coli were grown in suspension at 30° C. ambient temperature for ninety minutes. Then, their vessel was sealed and placed in a water bath at 46° C. for five minutes. Immediately following the heat shock, the vessel was placed on ice for one minute before a volume of 2% formaldehyde (equal to the volume of the suspension) was added to the suspension and mixed for suspension. Fixing cells were incubated at room temperature for one hour. After one hour, fixed cells were washed with 1×PBS and resuspended in 50% ethanol. A small volume (0.75 μL) was deposited on a glass slide and allowed to dry. The deposition was then rehydrated with 10 mg/ml lysozyme and placed at 37° C. for 15 minutes to encourage permeabilization. Cells were then washed with 1×PBS for ten minutes at room temperature. A hybridization buffer (2×SSC, 10% dextran sulfate, 10% ethylene carbonate, 5×Denhardt's solution, 0.01% SDS) containing rRNA (1 μM per species) and mRNA (1 μM per gene) was added to cells and the slide was placed at 37° C. for one hour. Immediately following hybridization, cells were incubated in wash buffer (5 mM EDTA, 20 mM Tris HCl, 215 mM NaCl) for 15 minutes at 48° C. Finally, the wash buffer was removed and the cells were mounted with Prolong Glass under a #1 coverslip for imaging.
DNA exchange was used as a method to quickly, specifically, carefully replace the HiPR-FISH readout probes without disturbing encoding and/or amplifier probes. This method is referred to as HiPR-Swap.
In the HiPR-Swap method, readout and encoding probes are designed such that the “landing pad” (the region on the encoding probe to which the readout probe binds) is complementary to the readout probe. In some instances, the landing pad sequence is shorter than the readout probe. This would create a single-stranded overhang of the readout probe, as it extends past the end of the landing pad (see
After a readout probe is bound, an exchange probe can be added to the specimen. The exchange probe is constructed to be of equal length and a perfect reverse complement to the readout probe. When added, the exchange probe seeds a hybridization to the exposed area of the readout probe (see
In theory, there is no limit to the number of times the assay can be performed. The maximum number of probes needed is the number of fluorescent probes observable in a single round (for example, 10) multiplied by the number of rounds. For example, if 4 rounds are performed, this will require 40 unique probes each bound with one of 10 fluorescent dyes. This would allow the target multiplexity to be (2{circumflex over ( )}(10)−1){circumflex over ( )}4=1,095,222,947,841 targets.
Advantages
Thermodynamics models can be applied to understand the extent to which probe swapping is likely to succeed. For example, the Boltzmann factor can be naively implemented to illustrate the improved likelihood of the readout-exchange probe duplex over the readout-encoding probe duplex (false assumption that the system is at equilibrium).
The probability of being in a state is given by the distribution:
Knowing this, one can find the Boltzmann factor as the ratio of probabilities (P(readout-exchange)/P(readout-encoding)).
The Boltzmann factor for various combinations of the readout probes was determined, where the overhang can be 1 to 5 nt from the 3′ or 5′ end (yellow or blue, respectively) and found that the likelihood of being in the readout-exchange state increases dramatically as the length of the overhang increases; the Boltzmann factor can exceed 10,000×.
HiPR-Swap, in combination with other technologies, will create a FISH-based assay with the highest multiplexity yet achieved. Its application to spectral barcoding and classification, to the study of microbiomes and bacteria, and its use to profile rRNA and mRNA (and potentially other analytes) make this method an improvement over the prior art.
An experiment was performed where three species of bacteria (Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae) were encoded with 18-24 encoding probes, with 15-nt landing pads. Each species was encoded such that they were hybridized with a single, unique bit (or dye).
The experiment was performed to (1) show the addition of exchange probes removes readout probes (and thereby fluorescence signal) and (2) following the exchange, new readout probes can be re-hybridized to the specimens without the addition of new encoding probes.
The procedure was as follows: Cells were adhered to a coverslip via evaporation. Each species of bacteria was separated from the others using a gasket. The cells were then digested with lysozyme at 37° C. for 30 minutes and washed with 1×PBS at room temperature for 15 minutes. The encoding probe hybridization and readout probe hybridization were performed in a single step. The hybridization buffer was prepared separately for each species (10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 400 nM of the readout probe, 2 uM per taxa of the encoding probes). The hybridization buffer was then added to the cells at 37° C. for 2 hours. The wash buffer (215 mM NaCl, 20 mM Tris-HCl (pH 8.0), and 5 mM EDTA) was then added to the cells at 30° C. for 15 minutes. The cells were imaged in the wash buffer. The cells were removed from the scope. The exchange buffer was then added to the cells at 37° C. and left overnight. The exchange buffer was prepared separately for each species (10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, and 2 uM of the exchange probe). The wash buffer was added to the cells at 30° C. for 15 minutes. The cells were imaged in the wash buffer. The readout buffer (prepared separately for each species: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, and 400 nM of the readout probe) was added to the cells and incubated at 37° C. for 2 hours. The wash buffer was added to the cells at 30° C. for 15 minutes. The cells were imaged in the wash buffer. The cells were removed from the scope and stored at 4° C.
As evidenced by
The encoding, readout, and exchange probes used in this example are shown in Table 5 below.
The experiment was continued after 5 days in the same samples as described in Example 6. To determine the timescale of the exchange reaction, the reaction was performed for 1 hour.
The experiment was performed to show that the stripping of readout probes can be achieved within 1 hour, as opposed to a longer period of time, such as over 12 hours.
The procedure was as follows. The cells were removed from the 4° C. refrigerator after 5 days and imaged in the wash buffer. The cells were removed from the scope and the exchange buffer was added to the cells at 37° C. for 1 hour. The wash buffer was then added to the cells at 30° C. for 15 minutes and the cells were imaged in the wash buffer. The encoding, readout, and exchange probes used in this example are shown in Table 5.
As can be seen in
This experiment was performed to show the sequential repeatability of the HiPR-Swap method and continues from Example 7.
After stripping the readout probes for 1 hour, the stripping reaction was continued overnight to remove the remaining readout probes. Following this, each species was encoded with the readout probes that correspond to their respective readout pads but tagged with the same dye (Alexa-488).
The procedure was as follows. The exchange buffer was added to the cells at 37° C. and left overnight. The wash buffer was then added to the cells at 30° C. for 15 minutes and the cells were imaged in the wash buffer. The cells were removed from the scope. A readout buffer was prepared separately for each species containing one of the following probes: R4-488, R6-488, R8-488. The readout buffer was then added to the cells and incubated at 37° C. for 2 hours. The wash buffer was added to the cells at 30° C. for 15 minutes and the cells were imaged in the wash buffer.
As shown in
Overall, these results demonstrate the full two cycles of HiPR-swap assay with robust removal and re-hybridization of the readout probes.
The R4-488, R6-488, R8-488 probes are shown in Table 6 below.
As shown in Examples 6-7, the readout probes can be removed (stripped) and replaced (swapped) in two subsequent steps. As long as the second round of readout probes differs from the first set that is being removed with exchange probes, the strip and swap can be performed in a single step.
Single-step HiPR-Swap and two-step HiPR-Swap was performed on a single slide with neighboring wells. In both wells, a mixture of E. coli and P. aeruginosa cells was adhered to the surface.
Round 1: In the first round for both wells, the taxa encoding probes for both species (including EUB which will serve as a tool to segment cells for analysis) were added and readout probes only for E. coli. The encoding and readout hybridization reactions were performed in a single step. Both wells were imaged following the first round of encoding and readout.
Round 2: In round two of the single-step well, the readout probes from E. coli were stripped and swapped with the readout probes for P. aeruginosa. For the two-step well, only the readout probes were stripped from E. coli. Both wells were imaged following this hybridization step.
Round 3: In round three of the single-step well, the readout probes from P. aeruginosa were stripped and swapped with the readout probes for E. coli. For the two-step well, only the readout probes were stripped from P. aeruginosa. Both wells were imaged following this hybridization step.
The experiment was conducted as follows mixtures of cells were adhered to a coverslip via evaporation. The cells were digested with lysozyme at 37° C. for 30 minutes. The cells were washed with 1×PBS at room temperature for 15 minutes.
Round 1: The encoding probe hybridization and readout probe hybridization were performed in a single step. The hybridization buffer was prepared as follows for both the wells: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 2 uM per taxa of the encoding probes, 400 nM of the Eubacterium probe, and 400 nM of the readout probe for E. coli. The hybridization buffer was added to the cells at 37° C. for 2 hours. The wash buffer (215 mM NaCl, 20 mM Tris-HCl (pH 8.0); and 5 mM EDTA) was added to the cells at 30° C. for 15 minutes. All wells were filled in excess with 2×SSC. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSC. Then, the cells were removed from the scope. The cells were washed with wash buffer for 1 min at RT. The cells were stored overnight in the wash buffer at 4° C.
Round 2: The exchange buffers were prepared separately for each well. Well: Single Step: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 6 uM of the exchange probe for E. coli, and 400 nM of the readout probes for P. aeruginosa. Well: Two Step: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, and 6 uM of the exchange probe for E. coli.
The exchange buffers were added to the cells at 37° C. for 2 hours. The wash buffer was added to the cells at 30° C. for 15 minutes. All wells were filled in excess with 2×SSC. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSC. The cells were removed from the scope. The cells were washed with wash buffer for 1 min at RT.
Round 3: The exchange buffers were prepared separately for each well. Well: Single Step: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 6 uM of the exchange probe for P. aeruginosa, and 400 nM of the readout probes for E. coli. Well: Two Step: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, and 400 nM of the readout probes probe for P. aeruginosa. The exchange buffers were added to the cells at 37° C. for 2 hours. The wash buffer was added to the cells at 30° C. for 15 minutes. All wells were filled in excess with 2×SSC. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSC. The encoding, readout, and exchange probes used in this example are shown in Table 5.
The single-step strip and swap reaction works equally well as the two-step reaction. This enables us to perform multiple rounds of HiPR-Swap (for example, at least 3 rounds for 30 bit barcode) in less than 12 hours.
As shown in
In single step condition, E. coli in round 1 is dimmer than the E. coli in round 3. This is likely because of the inefficient binding of readout probes to the readout pads in the first round of encoding/readout, where single step encoding and readout was used to perform HiPR-FISH. An addition of pre-hybridization incubation step before encoding/readout step can improve the binding efficiency of readout probes in round 1.
The single step strip and swap reaction was shown to work equally well as the two-step reaction. In this example, the single-step reaction was used to measure the stripping and swapping of the probes in real time.
Single-step HiPR-Swap was performed with a mixture of E. coli and P. aeruginosa cells.
Round 1: In the first round, the taxa encoding probes were added for both species and readout probes only for E. coli. The encoding and readout hybridization reactions were performed in a single step. The cells were imaged after this hybridization step.
Round 2: In the second round, the cells were placed under the microscope. the readout probes were stripped from E. coli and swapped with the readout probes for P. aeruginosa. Images were acquired while the stripping and swapping reaction was undergoing.
The following was performed in this example. Mixture of cells were adhered to a coverslip via evaporation. The cells were digested with lysozyme at 37° C. for 30 minutes and washed with 1×PBS at room temperature for 15 minutes. The pre-hybridization buffer (10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS) was added to the cells at 37° C. for 30 mins.
Round 1: The encoding probe hybridization and readout probe hybridization were performed in a single step. The hybridization buffer (both wells; 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 2 μM per taxa of the encoding probes, and 400 nM of the readout probe for E. coli) was added to the cells at 37° C. for 2 hours. The wash buffer (215 mM NaCl, 20 mM Tris-HCl (pH 8.0); and 5 mM EDTA) was added to the cells at 30° C. for 15 minutes. The cells were placed on the microscope and imaged under the wash buffer before acquiring the timelapse.
Round 2: The wash buffer was removed and the well was filled with the exchange buffer (10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 50 nM of the exchange probe for E. coli, and 25 nM of the readout probes for P. aeruginosa) under the microscope. The timelapse was started and images were acquired at a 15 seconds interval. The encoding, readout, and exchange probes used in this example are shown in Table 5.
As shown in
To capture the kinetics of this reaction, the reaction was purposefully slowed down dramatically by using a very low concentration of the exchange probes (50 nM) and the readout probes (25 nM). At higher concentrations, such as 2 uM for exchange probes and 400 nM for readout probes, in here the strip and swap reactions can be completed within a few minutes.
Notably, with the addition of the pre-hybridization step, the binding efficiency of the readout probes in the first round improved dramatically, as evident from the intensity of the “before” image in timelapse.
To show the full potential of using HiPR-Swap towards increasing the multiplexity of HiPR-FISH related assays, including HIPR-FAST and HIPR-cycle, the ability to identify over 1 billion taxa (or other targets; 1023{circumflex over ( )}3) in about 12 hours was shown.
This example was performed with E. coli bacteria bound to the coverslips in three wells. The bacteria in each well was encoded with a unique 30-bit barcode (e.g. 0110001000-0100100111-1101001000). The 30-bit experiment was performed in three rounds using HIPR-Swap, with each round containing up to 10-bits. A fourth round was added for error correction by going back to the same readouts as round 1.
Round 1: In the first round, the taxa encoding probes for bacteria were added in each well and incubated overnight. The first set of readout probes were added in each well. The cells were imaged after this hybridization step.
Round 2: In the second round, the first set of exchange probes to strip readout probes of round 1 was added, and second set of readout probes in each well. The cells were imaged after this hybridization step.
Round 3: In the third round, the second set of exchange probes to strip readout probes of round 2 was added, and third set of readout probes in each well. The cells were imaged after this hybridization step.
Round 4: In the fourth round, the third set of exchange probes to strip readout probes of round 3 were added, and first set of readout probes in each well. This was done to go back to the same sets of readout probes as used in round 1. The cells were imaged after this hybridization step.
The single step HiPR-Swap protocol was utilized as follows: cells were adhered to a coverslip via evaporation. The cells were digested with lysozyme at 37° C. for 30 minutes. The cells were washed with 1×PBS at room temperature for 15 minutes.
Round 1: The encoding buffer was prepared separately for each well as follows: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 2 μM each of encoding probes combination (C #, where #=readout probe #) as described below—
The encoding buffer was added to the cells at 37° C. and incubated overnight. The wash buffer was prepared as 215 mM NaCl, 20 mM Tris-HCl (pH 8.0), 5 mM EDTA. The wash buffer was added to the cells at 42° C. for 15 minutes. The readout buffer was prepared as follows 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, and 400 nM each of readout probe 11, 12, 13. The readout buffer was added to the cells at 37° C. for 1 hour. The wash buffer was added to the cells at 42° C. for 15 minutes. All wells were filled in excess with 2×SSCT. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSCT. The cells were removed from the scope. The cells were washed with 2×SSC for 1 min at RT.
Round 2: The exchange buffer for round 2 was prepared as follows 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 10 uM each of exchange probe 5, 8, and 10, 400 nM each of readout probe 14-17. The exchange buffer was added to the cells at 37° C. for 1 hour. The wash buffer was added to the cells at 42° C. for 15 minutes. All wells were filled in excess with 2×SSCT. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSCT. The cells were removed from the scope. The cells were washed with 2×SSC for 1 min at RT.
Round 3: The exchange buffer for round 3 was prepared as follows: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 10 uM each of exchange probe 14, 15, 17, 18, 400 nM each of readout probe 18-21. The exchange buffer was added to the cells at 37° C. for 1 hour. The wash buffer was added to the cells at 42° C. for 15 minutes. All wells were filled in excess with 2×SSCT. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSCT. The cells were removed from the scope. The cells were washed with 2×SSC for 1 min at RT.
Round 4: The exchange buffer for round 4 was prepared as follows: 10% ethylene carbonate, 10% dextran sulfate, 2×SSC, 5×Denhardt's solution, 0.01% SDS, 10 uM each of exchange probe 24, 25, 28, 30, 400 nM each of readout probe 11, 12, and 13. The exchange buffer was added to the cells at 37° C. for 1 hour. The wash buffer was added to the cells at 42° C. for 15 minutes. All wells were filled in excess with 2×SSCT. A glass coverslip was placed on top of the wells to minimize evaporation. The cells were imaged under 2×SSCT.
Microscopy
As indicated above, in each round, imaging using confocal microscopy (Zeiss i880 confocal microscope) with emission collected was collected on a spectral detector between roughly the excitation wavelength and 693 nm in 8.9 nm bins. A Plan-Apochromat 63×/1.4 Oil DIC M27 was used and collected data as 2000×2000 pixel images (134.95 μm×134.95 μm). The laser settings for the example were as shown in Table 6 below.
The encoding, readout, and exchange probes used in this example are shown in table 7 below.
To examine the ability to perform HiPR-Swap on a tissue specimen (colon of a healthy mouse) probes were designed to perform a simple taxon identification experiment, barcoding the six most abundant bacteria phyla with either one or two readout probes, such that each readout probe was only present in one of three imaging rounds. As shown in
Phylum-level swap protocol: OCT (optimal cutting temperature)-embedded formalin-fixed tissue was sectioned at 10-micron thickness onto circular glass coverslips made for Bioptechs FCS2 flow cell. The tissue was covered with 2% formaldehyde for two hours at room temperature to fix the sample. The sample was washed by removing the buffer and replacing it with 1×PBS for 5 minutes (this was repeated two more times). The fixed tissue specimen was stored in 70% ethanol at 4° C. overnight. The following buffers were prepared:
Place 10 mg/mL lysozyme to completely cover the specimen and incubate for 30 minutes at 37° C. in a humidified chamber. Wash the specimen with 1×PBS for 15 minutes at room temperature. Dry the specimen by submerging it in 100% ethanol and allowing it to air dry. Place the coverslip on the FCS2 flow cell (Bioptechs) and assemble. Place the flow cell assembly on the microscope stage (Zeiss i880 confocal). Connect the flow cell input port to the Aria Automated Perfusion System (Fluigent). Calibrate the Aria Automated Perfusion System using DI water. Load encoding, readout buffers, wash buffer, 1×PBS buffer, 5×SSC+DAPI buffer (40 ng/mL DAPI in 5×SSC), and 2×SSC buffer into Aria Automated Perfusion System at the desired reservoir locations. Execute the following sequence on the Aria:
Table 8 shows the encoding, readout, and exchange probe sequences used in this example.
To extend the ability to perform HiPR-Swap at the phylum level on a tissue specimen (colon of a healthy mouse) to the species level probes to perform a simple taxon identification experiment were designed, barcoding the sixty-five most abundant species in healthy mouse stool (measured internally by PacBio 16S long-read sequencing). As shown in
Species-level swap protocol: OCT-embedded formalin-fixed tissue was sectioned at 10-micron thickness onto circular glass coverslips made for Bioptechs FCS2 flow cell. The tissue was covered with 2% formaldehyde for two hours at room temperature to fix the sample. The sample was washed by removing the buffer and replacing it with 1×PBS for 5 minutes (this was repeated two more times). The fixed tissue specimen was stored in 70% ethanol at 4° C. overnight. The following buffers were prepared:
Place 10 mg/mL lysozyme to completely cover the specimen and incubate for 30 minutes at 37° C. in a humidified chamber. Wash the specimen with 1×PBS for 15 minutes at room temperature. Dry the specimen by submerging it in 100% ethanol and allowing it to air dry. Place the coverslip on the FCS2 flow cell (Bioptechs) and assemble. Place the flow cell assembly on the microscope stage (Zeiss i880 confocal). Connect the flow cell input port to the Aria Automated Perfusion System (Fluigent). Calibrate the Aria Automated Perfusion System using DI water. Load encoding, readout buffers, wash buffer, 1×PBS buffer, 5×SSC+DAPI buffer (40 ng/mL DAPI in 5×SSC), and 2×SSC buffer into Aria Automated Perfusion System at the desired reservoir locations. Execute the following sequence on the Aria:
Table 9 shows the encoding, readout, and exchange probe sequences used in this example.
Although the present disclosure has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the disclosure. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present disclosure. All such modifications are intended to be within the scope of the claims appended hereto.
This application claims the benefit of U.S. Provisional Application No. 63/282,947, filed on Nov. 24, 2021, and U.S. Provisional Application No. 63/339,291, filed on May 6, 2022. The entire contents of the aforementioned applications are incorporated herein by reference in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| 63339291 | May 2022 | US | |
| 63282947 | Nov 2021 | US |
